Dexcom (DXCM) 10-K risk factor changes: FY2021 vs FY2020
The 2021-12-31 10-K against the 2020-12-31 one, compared heading by heading and sentence by sentence.
Item 1A172 rewritten73 added77 removed956 unchanged
All filing items964 rewritten439 added503 removed2,236 unchanged
Sentence counts leave out repeated page headers and footers. 5 of those lines differ and are listed apart under each item.
Summary
counted, not written
- Item 1A lists 76 risk factor headings: 2 new, 9 reworded and 65 unchanged since FY2020. 1 heading from FY2020 no longer appears.
- Sentence by sentence, 439 added, 503 removed, 964 rewritten and 2,236 unchanged across 18 items that differ.
- Not counted above: 5 repeated page header or footer lines also differ. They are listed apart under each item.
- New this year: Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.
New Item 1A headings (2)
- Cyber attacks aimed at accessing our devices, products, and services, or related devices, products, and services, and modifying or using them in a way inconsistent with our FDA clearances and approvals, could create risks to users.Cybersecurity
- Climate change may have a long-term impact on our business.
Removed Item 1A headings (1)
- Unauthorized third parties may seek to access our devices or other products and services, or related devices, products, and services, and modify or use them in a way inconsistent with our FDA clearances and approvals, which may create risks to users.
Reworded Item 1A headings (9)
- We are subject to cost-containment efforts [added: by third-party payors] that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.
- Our products may not achieve [added: or maintain] market acceptance.
- The outbreak of the SARS-CoV-2 virus and [added: its variants and] the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
- We are subject to complex and evolving U.S. and foreign laws and regulations [added: and other requirements] regarding privacy, data protection, [added: security,] and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
- Security breaches and other disruptions
[removed: could][added: that] compromise our information and expose us to liability,[removed: which would][added: could] cause our business and reputation to suffer and could subject us to substantial liabilities. - We may be subject to fines, penalties and injunctions if we are determined to be promoting the use of our products for unapproved or improper off-label uses or determined to have made claims that
[removed: untruthful or misleading or not adequately substantiated or determined to have made claims that][added: are] untruthful or misleading or not adequately substantiated. - Failure to comply with covenants in
[removed: our revolving credit agreement with JPMorgan Chase Bank and other syndicate lenders][added: the Amended Credit Agreement] could result in our inability to borrow additional funds and adversely impact our business. - Current uncertainty in [added: domestic and] global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.
- Environmental, social and corporate
[removed: governance (ESG)][added: governance, or ESG] regulations, policies and provisions may make our supply chain more complex and may adversely affect our relationships with customers.
A heading is new when no FY2020 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
23 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2021; struck-through words were in FY2020. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. RISK FACTORS
172 rewritten, 73 added, 77 removed, 956 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
[removed: - We] [added: We] are subject to cost-containment efforts [added: by third-party payors] that could result in reduced product pricing and/or sales of our products and cause a reduction in future [removed: revenue.][added: revenue.]
[removed: - Our] [added: Our] products may not achieve [added: or maintain] market [removed: acceptance.][added: acceptance.]
[removed: - The] [added: The] outbreak of the SARS-CoV-2 virus and [added: its variants and] the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and [removed: sales.][added: sales.]
[removed: - We] [added: We] are subject to complex and evolving U.S. and foreign laws and regulations [added: and other requirements] regarding privacy, data protection, [added: security,] and other matters.
The [removed: global] COVID-19 pandemic may result in increased costs for manufacturing and outsourced services while also causing additional pressure to reduce the prices for our products if a recession or depression occurs and people are unable to afford our products.
[added: We] expect that the continuing cost reduction and containment measures may reduce the cost or utilization of health care products and could lead to patients being unable to obtain approval for coverage or payment from these third-party payors.
Additionally, as a result of [removed: COVID-19,] [added: the COVID-19 pandemic,] some customers have and others may lose access to their private health insurance plan if they lose their job, and an impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our customer.
On October 27, 2020, CMS proposed changes to Medicare Durable Medical Equipment, Prosthetics, Orthotic Devices, and [removed: Supplies (DMEPOS)] [added: Supplies, or DMEPOS,] coverage and payment policies that would expand Medicare coverage for CGM devices and supplies by classifying all CGMs (not just therapeutic CGMs) as DME and establishing payment amounts for these items and related supplies.
[removed: If finalized, beginning April 2021,] [added: The fee schedule amounts for the newly-covered adjunctive CGMs and related supplies will be established in accordance with existing regulations governing pricing for new DME items without a fee schedule pricing history The expanded coverage for CGMs means that] additional manufacturers would be able to obtain Medicare coverage and payment for their CGM devices and some of the new CGM options may be cheaper for Medicare beneficiaries, potentially resulting in decreased sales and resulting revenues.
As of December 31, [removed: 2020,] [added: 2021,] the [removed: seven] [added: eight] largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices.
In addition, we have negotiated contracted rates with all [removed: seven] of those third-party payors for the purchase of our current CGM systems by their members.
In addition, Medicare, Medicaid, other governmental health programs, health maintenance organizations and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of [added: new and existing medical devices, and, as a result, they may be restrictive, or they may not cover or provide adequate payment for our products.]
Our dependence on the commercial success of our current CGM systems makes us particularly susceptible to any cost [removed: containment or reduction efforts.]
Medicare does not cover any items or services that are not “reasonable and necessary.” Medicare covers the CGM system, which includes supplies necessary for the use of the device, under the Durable Medical [removed: Equipment (DME)] [added: Equipment, or DME,] benefit category.
The development of new products, or novel technologies and services and the enhancement of our current CGM products (including [added: seeking and] obtaining new indications for use), requires significant investment in research and development, intellectual property protection, clinical trials, regulatory approvals and third party reimbursement.
The results of our product development and commercialization efforts may be affected by a range of factors, including our ability to anticipate customer needs, innovate and develop new products, [added: determine a feasible or timely regulatory pathway or approach,] and launch those products cost effectively into multiple markets and geographies.
In the ordinary course of our business, we enter into collaborative arrangements to develop new products and to pursue new markets, such as our agreements with Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes and The Ypsomed Group, to integrate our CGM technology into their insulin delivery systems, and our amended agreement with Verily to develop one or [added: more next-generation CGM products.]
In the event of such a termination, we may be required to devote additional resources to product development and commercialization, we may need to cancel some development programs and we may face increased [removed: competition.]
- the introduction and market acceptance of competing products and technologies, which may have a lower cost or price, allow for a convenience improvement [removed: and] [added: and/or] allow for improved accuracy and reliability;
- our inability to obtain sufficient quantities of supplies [added: timely and] at appropriate quality levels from our single- or sole-source and other key suppliers;
[removed: If our CGM systems do not achieve and maintain an adequate level of acceptance by people] with diabetes, healthcare professionals, including physicians, and third party payors, our future revenue may be reduced and our business may be harmed.
In addition, we will have to modify our manufacturing design, reliability and process if and when our next-generation [removed: CGM,] [added: CGM] technologies are approved, cleared or otherwise authorized by the applicable regulatory body and commercialized.
If an event occurs at one of our facilities that results in damage to, or closure of, one or more of such facilities, [added: or if our distributions from those facilities are limited or restricted in any way,] we may be unable to manufacture the relevant products at the previous levels or at all.
[removed: In the event our existing manufacturing facilities or equipment are affected by man-made] [added: made] or natural disasters, we may be unable to manufacture products for sale or meet customer demands or sales projections.
Our contract manufacturers may also rely on [removed: single-or sole- source] [added: single- or sole-source] suppliers to manufacture some of the components used in our products.
Although we work with our suppliers to try to ensure continuity of supply while maintaining quality, timeliness and reliability, the supply of these components, materials and services [added: has in some cases been, and] may [added: continue to] be impacted, interrupted or insufficient.
Our manufacturers and suppliers may also experience or be impacted by equipment malfunction, environmental factors, and public health emergencies including but not limited to the [removed: global] COVID-19 pandemic, any of which could delay or impede their ability to meet our demand.
For supply risks related to [removed: COVID-19,] [added: the COVID-19 pandemic] see [added: our Risk Factor entitled,] *“The outbreak of the SARS-Cov-2 virus and [added: its variants and] the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.”*
- we are not a major customer of many of our suppliers, and these suppliers may therefore give other customers’ [added: needs higher priority than ours;]
- our suppliers manufacture products for a range of customers, and fluctuations in demand for the products these suppliers manufacture for others may affect their ability to deliver components to us in a timely [removed: manner;][added: manner or at the current pricing;]
- effectively train our sales and marketing personnel on the applicable advertising and promotion, and fraud and abuse laws that govern interactions with healthcare [removed: practitioners] [added: professionals and institutions] as well as current and prospective patients and maintain active oversight and auditing measures to ensure continued compliance.
[added: COVID-19 restrictions vary by location across the United States and other regions of the world, which may continue to limit or] prohibit our sales force from having in-person interactions with healthcare [removed: providers] [added: professionals] and people with diabetes, which may result in decreased sales of our products.
Our distribution agreements with Byram and affiliates, Cardinal Health and affiliates (including Edgepark Medical Supplies), AmerisourceBergen, and McKesson, our four most significant distributors, each generated 10% or more of our total revenue during the twelve months ended December 31, [removed: 2020.][added: 2021.]
[removed: Moreover our shift of durable medical] equipment sales from our direct sales force to distributors could result in negative impacts on the quality or efficacy of our customer sales and support experience.
The outbreak of the SARS-CoV-2 virus and [added: its variants and] the COVID-19 disease that it causes [removed: is] [added: has been and continues to be] a global pandemic.
The novel coronavirus [removed: has] [added: as well as new variants of the coronavirus have] spread to most regions of the world, including the United States and Europe.
The extent to which this coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new [added: variants of the virus and new] information that may emerge concerning the virus and the actions to contain it or to mitigate the COVID-19 impact, among others.
The COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we [added: have, and] may [removed: begin] [added: continue] to experience more pronounced disruptions in our operations.
For example, there [added: have been and] could [added: continue to] be delays in FDA review of applications for marketing authorization, including those which may be necessary for or in connection with proposed changes to our products or the changes to the processes by which they are manufactured.
Any elongation or [removed: de-prioritization] [added: deprioritization] or delay in regulatory review resulting from such disruptions could materially affect our ongoing device design, development, and commercialization plans.
CMS finalized its proposal on December 21, 2021, expanding Medicare coverage for all types of CGMs.
CGMs will now be categorized as adjunctive and non-adjunctive (i.e., therapeutic CGMs).
Effective July 18, 2021, CMS also amended local coverage determination L33822 to allow beneficiaries with diabetes to use CGM when prescribed “multiple daily administrations” of insulin, eliminating the “injection” requirement and the four times per day testing requirement for CGM coverage.
containment or reduction efforts.
competition.
If our CGM systems do not achieve and maintain an adequate level of acceptance by people
In the event our existing manufacturing facilities or equipment are affected by man-
Moreover our shift of durable medical
It is especially difficult to predict the impact on the global economic markets, which have been and will continue to be highly dependent upon the actions of governments, businesses, and other enterprises in response to the pandemic, as well as the effectiveness of those actions, and vaccine availability, distribution, efficacy and adoption.
restrictions resulting from, the COVID-19 pandemic, our supply chain may be continue disrupted, limiting our ability to manufacture our devices.
On June 15, 2021, the Governor terminated the executive orders that put into place the Stay Home Order and as well as the framework for a gradual, risk-based reopening of the economy (Executive Order N-60-20, issued on May 4, 2020, which issued the Blueprint for a Safer Economy).
He also phased out the vast majority of executive actions put in place since March 2020 as part of California’s response to the COVID-19 pandemic, leaving a subset of provisions that facilitate the ongoing recovery.
Nonetheless, we continue to take precautions to protect the health and safety of our employees, including contact tracing, requiring masks for onsite employees and providing access to onsite vaccination clinics.
Moreover, the tax laws in which we and our subsidiaries do business could change on a prospective or retroactive basis, and any such changes could adversely affect our business and financial condition.
There is growing pressure in many jurisdictions, including the United States, and from multinational organizations such as the Organization for Economic Cooperation and Development, or OECD, and the European Union to amend existing international tax rules in order to render them more responsive to current global business practices.
For example, the OECD has published a package of measures for reform of the international tax rules as a product of its Base Erosion and Profit Shifting, or BEPS, initiative, which was endorsed by the G20 finance ministers.
Many of the initiatives in the BEPS package require amendments to the domestic tax legislation of various jurisdictions.
Separately, the European Union is asserting that a number of country-specific favorable tax regimes and rulings in certain member states may violate, or have violated, European Union law, and may require rebates of some or all of the associated tax benefits to be paid by benefited taxpayers in particular cases.
In 2016, the European Union adopted the "Anti-Tax Avoidance Directive," which requires European Union member states to implement measures to prohibit tax avoidance practices, and Germany published the European Union Anti-Tax Avoidance Directive Implementation Law on June 30, 2021.
We have a significant presence in the European Union, as well as significant sales in the European Union, such that any changes in tax laws in the European Union will impact our business.
The overall impact of such legislation in European Union member states is uncertain, and our business and financial condition could be adversely affected by any laws impacting our tax rate.
In addition, a recession, depression or other
As our customer base grows to include U.S. federal government agencies, Dexcom may also need comply with Federal Risk and Authorization Management Program and Cybersecurity Maturity Model Certification requirements.
These frameworks impose stringent cybersecurity standards and potentially significant non-compliance penalties.
Dexcom is a covered entity under HIPAA and may also function in a business associate capacity to other covered entities.
There are also a number of other legislative proposals worldwide, including in the United States at both the federal and state level, that could impose additional and potentially conflicting obligations in areas affecting our business.
The GDPR also requires companies processing personal
These threat actors may be able to penetrate our security measures, breach our information technology systems, misappropriate or compromise confidential and proprietary information of our company and our customers, cause system disruptions and shutdowns, or introduce ransomware, malware, or vulnerabilities into our products, systems, and networks or those of our customers and partners.
We are and may continue to be subject to cybersecurity incidents that bypass our security measures.
In addition, certain countries have implemented or may implement legislative and technological actions that either do or can effectively regulate access to the internet, including the ability of internet service providers to limit access to specific websites or content.
Other countries have attempted or are attempting to change or limit the legal protections available to businesses that depend on the internet for the delivery of their services.
- the dispensing of our products;
The risk of being found in violation of these laws and regulations is
As part of our compliance program, we have reviewed our sales contracts, marketing materials, referral source relationships, programmatic offerings, and billing
Private third-party payors, as well as governments,
The new rule which was initially to go into effect January 1, 2022, will now not become effective until January 2026 at the earliest, due to a number of federal administrative and legislative developments.
Given the delay of the implementation of the new rule until at least January 2026, we do not expect significant restructuring of our PBM relationships in the near term.
regulatory approval.
Extension of CGM system use to
If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or
| Summary of Risk Factors | | | | | | | | | | | | | | |
The below summary of risk factors provides an overview of many of the risks we are exposed to in the normal course of our business activities.
As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading “Risk Factors,” as well as elsewhere in this Annual Report on Form 10-K.
Additional risks, beyond those summarized below or discussed elsewhere in this Annual Report on Form 10-K, may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate.
Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with the following:
- If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
- If we are unable to obtain adequately broad reimbursement at acceptable prices for our products or any future products from third-party payors, our revenue may be negatively impacted.
- The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.
- If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, we may not be able to meet market demand or our growth could be limited and our business could be harmed.
- Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales and increase our expenses.
- We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.
- If we are unable to continue the development of an adequate sales and marketing organization and/or if our direct sales organization is not successful, or enter into and maintain arrangements with third parties to sell, market or distribute our products, we may have difficulty achieving market awareness and selling our products in the future.
- We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.
- We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.
- We have incurred significant losses in the past and may incur losses in the future.
Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
- Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.
- We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.
- Managed care trends, consolidation in the health care industry and health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.
- If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.
- We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief.
We may also be subject to other claims or suits.
- Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.
- We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.
- We could become the subject of governmental investigations, claims and litigation.
- Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.
- We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.
We are subject to cost-containment efforts that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.
We
new and existing medical devices, and, as a result, they may be restrictive, or they may not cover or provide adequate payment for our products.
more next-generation CGM products.
Our products may not achieve market acceptance.
needs higher priority than ours;
Current shelter-in-place orders limit or
The outbreak of the SARS-CoV-2 virus and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
“Essential” employees that are unable to telework continue to work at our facilities, and we have implemented appropriate safety measures, including social distancing, face covering, and increased sanitation standards.
- the potential payment of U.S. income taxes on certain earnings of our subsidiaries outside the United States upon repatriation.
will effectively prevent us from violating these regulations in every transaction in which we may engage.
required to obtain FDA marketing authorization(s).
We are subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and other matters.
An excerpt. Shown here: 40 of 172 rewritten, 40 of 73 added and 40 of 77 removed. The counts are complete. For every sentence, read Item 1A. RISK FACTORS in the FY2021 filing and the FY2020 filing.
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
76 rewritten, 87 added, 168 removed, 68 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
You should read the following discussion and analysis together with [removed: “Selected Financial Data” in Part II, Item 6 and] our consolidated financial statements and related notes in Part II, Item 8 of this Annual Report.*
[added: | | | | | | |] We have built a direct sales organization in the United States, [removed: Canada] [added: Australia, Canada, New Zealand,] and certain countries in Europe to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. [added: To complement our direct sales efforts, we have entered into distribution arrangements in the United States, and certain countries in Africa, Asia, Europe, Latin America, and the Middle East, as well as Australia, Canada, and New Zealand that allow distributors to sell our products. | | |]
[added: | | | | | | | Product Development:] We [added: plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We] also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior. [added: | | |]
[added: | | | | | | | Partnerships:] We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. [added: | | |]
[added: | | | | | | | New Opportunities:] We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. [added: Eventually, we may apply our technological expertise to products beyond glucose monitoring. | | |]
For discussion related to the results of operations and changes in financial condition for fiscal [removed: 2019] [added: 2020] compared to fiscal [removed: 2018] [added: 2019] refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our [removed: fiscal 2019] [added: 2020 Annual Report on] Form 10-K, which was filed with the United States Securities and Exchange Commission on February [removed: 13, 2020.][added: 11, 2021.]
See [removed: “Risk Factors”] [added: Note 5 “Debt” to the consolidated financial statements] in Part [removed: I,] [added: II,] Item [removed: 1A] [added: 8] of this Annual Report for further discussion of the [removed: possible impact] [added: terms] of [removed: the COVID-19 pandemic on] our [removed: business.][added: senior convertible notes.]
| Critical Accounting [removed: Policies and] Estimates | | | | | | | | | | | | | | |
While our significant accounting policies are [removed: more fully] described in Note 1 to the consolidated financial statements in Part II, Item 8 of this Annual Report, we believe that the following accounting [removed: policies and] estimates are most critical to a full understanding and evaluation of our reported financial results.
Members of our senior management have discussed the development and selection of these critical accounting [removed: policies] [added: estimates] and their disclosure in this Annual Report with the Audit Committee of our Board of Directors.
[removed: *Revenue Recognition*][added: Revenue]
We estimate provisions for [added: pharmacy] rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.
Estimates associated with rebates on products sold through our distributors under pharmacy benefits are the most significant component of our variable consideration estimates and most at risk for [removed: changes] [added: material adjustment because of the time delay] between the recording of the accrual estimate and its ultimate settlement, an interval that [removed: can] generally [removed: range] [added: ranges from 30 to 90 days, but can last] up to one year.
Due to this time lag, in any given period, our adjustments to [removed: actuals] [added: reflect actual amounts] can incorporate changes of estimates related to prior periods.
For more information, see [removed: *“Revenue Recognition”*] [added: *Revenue Recognition*] in Note 1 to the consolidated financial statements in Part II, Item 8 of this Annual Report.
See [removed: Note 1 and] [added: *Leases* in] Note [removed: 3] [added: 6] to the consolidated financial statements in Part II, Item 8 of this Annual Report for more [removed: information about fair value measurements.][added: information.]
[removed: *Excess] [added: Excess] and Obsolete [removed: Inventory*][added: Inventory]
[removed: *Income Taxes*][added: Income Taxes]
We use the asset and liability approach to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax [removed: bases] [added: basis] of assets and [removed: liabilities.][added: liabilities as described in Note 1 to the consolidated financial statements in Part II, Item 8 of this Annual Report.]
[removed: We maintain the valuation allowance on our California research and] development tax [removed: credits] [added: credits, foreign tax credits,] and certain foreign intangible assets, as it is more likely than not that those deferred tax assets will not be realized.
We recognize and measure benefits for uncertain tax positions using a two-step [removed: approach.][added: approach as described in Note 1 to the consolidated financial statements in Part II, Item 8 of this Annual Report.]
[removed: *Loss Contingencies*][added: Loss Contingencies]
| | | | Twelve Months Ended December 31, | | | | | | | | | | | | [removed: 2020 - 2019] | | | | | | | | | | | | [removed: | | | | | |] [added: 2021 - 2020] | | | | | | | | |
| Operating income | | | [removed: 299.5 | | | | | | 142.3] [added: 265.8] | | | | | | [added: 11] | | [added: %] | | | | [removed: 157.2] [added: 299.5] | | | | | | [removed: *] [added: 16] | | [added: %] | | | | [added: (33.7)] | | | | | | [added: (11)] | | [added: %] |
| Net income | | | [removed: 493.6 | | | | | | 101.1] [added: $] | [added: 154.7] | | | | | [added: 6] | | [added: %] | | | | [removed: 392.5] [added: $] | [added: 493.6] | | | | | [removed: *] [added: 26] | | [added: %] | | | | [added: $] | [added: (338.9)] | | | | | [added: (69)] | | [added: %] |
[added: |] * Not meaningful [added: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |]
| [removed: | | |] Twelve Months Ended December [removed: 31, | | |] [added: 31, 2021 Compared to Twelve Months Ended December 31, 2020] | | | | | | | | | [removed: 2020 - 2019] | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cost of sales | | | [removed: 646.6 | | | | | | 544.5] [added: 768.0] | | | | | | [added: 31] | | [added: %] | | | | [removed: 102.1] [added: 646.6] | | | | | | [removed: 19] [added: 34] | | % | | | | [added: 121.4] | | | | | | [added: 19] | | [added: %] |
We expect that [removed: revenues] [added: revenue] we generate from the sales of our products will fluctuate from quarter to quarter.
[added: Factory overhead includes facilities,] material procurement and control, manufacturing engineering, quality assurance, supervision and management.
[added: | Revenue | | | | | |] The [removed: 2020] revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base, partially offset by [removed: pricing pressure due to] [added: mix shift and price associated with] the evolution of our channel [removed: strategy] [added: strategy. Disposable sensor] and [removed: product mix.][added: other revenue comprised approximately 84% of total revenue and Reusable Hardware revenue comprised approximately 16% of total revenue for the twelve months ended December 31, 2021. Disposable sensor and other revenue comprised approximately 81% of total revenue and Reusable Hardware revenue comprised approximately 19% of total revenue for the twelve months ended December 31, 2020. | | |]
[added: | Cost of Sales & Gross Profit | | | | | | Cost of sales increased primarily due to an increase in sales volume.] The increase in gross profit and gross profit margin in [removed: 2020] [added: 2021] compared to [removed: 2019] [added: 2020] were primarily driven by increased [removed: revenues] [added: revenue] and cost savings associated with incremental improvements to product [removed: design and] [added: design,] manufacturing [removed: efficiencies.][added: efficiencies and economies of scale. | | |]
| [removed: Operating Expenses] [added: Operating expenses:] | | | | | | | | | | | | | | | [added: | | | | | | | | | | | | | | | | | | | | |]
| | | | [added: | | |] Twelve Months Ended December [removed: 31, | | | | | | | | | | | | | | | 2020 - 2019 | | | | | | | | | | | | | | | | | | | | |] [added: 31, 2021 Compared to Twelve Months Ended December 31, 2020] | | |
| Research and development | | | [removed: $ | 359.9 | | | | | $] [added: 517.1] | [removed: 273.5] | | | | | [added: 21] | | [added: %] | | | | [removed: $] [added: 359.9] | [removed: 86.4] | | | | | [removed: 32] [added: 19] | | % | | | | [added: 157.2] | | | | | | [added: 44] | | [added: %] |
[removed: | Selling, general] [added: Selling, General] and [removed: administrative | | | 620.7 | | | | | | 515.7 | | | | | | | | | | | | 105.0 | | | | | | 20 | | % | | | | | | | | | | | | |][added: Administrative]
| Total operating expenses | | | [removed: $ | 980.6 | | | | | $] [added: 1,414.7] | [removed: 789.2] | | | | | [added: 58] | | [added: %] | | | | [removed: $] [added: 980.6] | [removed: 191.4] | | | | | [removed: 24] [added: 51] | | % | | | | [added: 434.1] | | | | | | [added: 44] | | [added: %] |
[added: | Research and Development Expense | | | | | | Research and development expense increased primarily due to $62.7 million in additional third party and consulting fees primarily related to software development for new products and significant enhancements, $49.1 million in additional salaries, bonuses, and payroll-related costs primarily due to higher headcount, and $13.2 million in additional clinical trials costs related to pivotal trials.] We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy. [added: | | |]
[removed: *Interest Expense*][added: | Interest expense | | | (100.3) | | | | | | (4) | | % | | | | (84.7) | | | | | | (4) | | % | | | | (15.6) | | | | | | 18 | | % |]
[removed: *Loss] [added: | Loss] on [removed: Extinguishment] [added: extinguishment] of [removed: Debt*][added: debt | | | (1.5) | | | | | | — | | % | | | | (5.9) | | | | | | — | | % | | | | 4.4 | | | | | | (75) | | % |]
| | | | WHO WE ARE | | | | | |  | | |
| | | | We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation system, the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in 2018. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries. | | | | | | | | |
|  | | | | | | Global Presence | | |
| | | | | | |  | | |
|  | | | | | | Future Developments | | |
|  | | | | | | | | | | | | | | |
|  | | | | | | Impact of COVID-19 Pandemic | | | | | | | | |
| | | | | | | During 2020 and 2021, we have been subject to challenging social and economic conditions created as a result of the novel strain of coronavirus, SARS-CoV-2, or COVID-19. These conditions continue to create various financial impacts to our operations by necessitating precautions for our personnel to operate safely both in person as well as remotely. Costs incurred include items like incremental payroll costs, consulting support, IT infrastructure and facilities-related costs. | | | | | | | | |
| | | | | | | As the result of the COVID-19 pandemic, we made Dexcom CGM systems available for use in hospital settings and other healthcare facilities to assist frontline workers. The extent of the impact of the COVID-19 pandemic on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers and our sales cycles, employee or industry events, and effect on our vendors, all of which are uncertain and cannot be predicted. The COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we have experienced moderate disruptions in our global operations. We have experienced and may experience constrained supply or curtailed customer demand, including due to customer loss of private health insurance coverage for our products, that could materially adversely impact our business, results of operations and overall financial performance in future periods. We currently utilize third parties to, among other things, manufacture components and materials for our devices, and to provide services such as sterilization services and we purchase these materials and services from numerous suppliers worldwide. | | | | | | | | |
| | | | | | | The COVID-19 pandemic has and may continue to have an adverse impact on our manufacturing and distribution capabilities. Disruptions relating to the COVID-19 pandemic, including shelter-in-place orders in the U.S. and other countries, could prevent employees, suppliers, distributors, and others from accessing manufacturing facilities and from transporting our products or the components required to manufacture our products. For example, we have experienced some supply chain disruption due to the global restrictions resulting from the COVID-19 pandemic in the manufacturing of our next-generation CGM product. Further, worldwide supply chain disruption relating to the COVID-19 pandemic has resulted in product shortages that has and may continue to impact our ability to manufacture our devices. As of the filing date of this Annual Report, the extent to which COVID-19 may impact our financial condition or results of operations or guidance is uncertain. The effect of the COVID-19 pandemic will not be fully reflected in our results of operations and overall financial performance until future periods. See “Risk Factors” in Part I, Item 1A of this Annual Report for further discussion of the possible impact of the COVID-19 pandemic on our business. | | | | | | | | |
Variability reflected in the sensitivity analysis presented below is based on our recent historical experience.
Pharmacy Rebates
Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenue.
An increase or decrease of 1% in our estimate of products sold subject to rebate during 2021, holding all other assumptions constant, would increase or decrease revenue by approximately $11.5 million.
We assess the value of our inventory on a quarterly basis and write down those inventories based on quality control testing data, obsolescence, or in excess of our forecasted demand to the lower of their cost or net realizable value.
Our estimates of forecasted demand are based upon our analysis and assumptions including, but not limited to, expected product lifecycles, product development plans and historical usage by product.
If actual market conditions are less favorable than our forecasts, or actual demand from our customers is lower than our estimates, we may be required to record additional inventory write-downs.
If actual market conditions are more favorable than anticipated, inventory previously written down may be sold, resulting in lower cost of sales and higher income from operations than expected in that period.
We maintain a valuation allowance on our California research and
| Overview of Financial Results | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| The most important financial indicators that we use to assess our business are revenue growth, gross profit, operating income, net income, and cash flow from operations. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Key highlights for fiscal 2021 include the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenue | | | | | | | | | Gross Profit | | | | | | | | | Operating Income | | | | | | | | | Net Income | | | | | | | | | Operating Cash Flow | | |
| $2.45 billion | | | | | | | | | $1.68 billion | | | | | | | | | $265.8 million | | | | | | | | | $154.7 million | | | | | | | | | $442.5 million | | |
| up 27% from 2020 | | | | | | | | | up 31% from 2020 | | | | | | | | | down 11% from 2020 | | | | | | | | | down 69% from 2020 | | | | | | | | | down 7% from 2020 | | |
We ended fiscal 2021 with cash, cash equivalents and short-term marketable securities totaling $2.73 billion.
| Business Trends | | | | | | | | | | | | | | |
In addition to the general impacts of COVID-19 on our company as described in the Overview, looking ahead we expect our business could be affected by the following:
- Increase in the worldwide incidence of people diagnosed with diabetes and costs related to the management and treatment of diabetes.
- Changes in medical reimbursement policies and programs.
- Growing demand for digital health technologies by both healthcare providers and consumers to reduce costs, empower consumers to make better-informed decisions about their own health and provide new options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional health care settings.
- Continued product innovation and competition from other CGM device makers.
- Our ability to scale efficiently with the construction of our production facility in Malaysia.
*•*Our ability to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, in particular, our next generation G7 CGM system.
| *(In millions, except per share amounts)* | | | 2021 | | | | | | % of Revenue (1) | | | | | | 2020 | | | | | | % of Revenue (1) | | | | | | $ Change | | | | | | % Change | | |
| Revenue | | | $ | 2,448.5 | | | | | 100 | | % | | | | $ | 1,926.7 | | | | | 100 | | % | | | | $ | 521.8 | | | | | 27 | | % |
| Gross profit | | | 1,680.5 | | | | | | 68.6 | | % | | | | 1,280.1 | | | | | | 66.4 | | % | | | | 400.4 | | | | | | 31 | | % |
| Collaborative research and development fee | | | 87.1 | | | | | | 4 | | % | | | | — | | | | | | — | | % | | | | 87.1 | | | | | | * | | |
| Selling, general and administrative | | | 810.5 | | | | | | 33 | | % | | | | 620.7 | | | | | | 32 | | % | | | | 189.8 | | | | | | 31 | | % |
| Income before income taxes | | | 173.9 | | | | | | 7 | | % | | | | 225.0 | | | | | | 12 | | % | | | | (51.1) | | | | | | (23) | | % |
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for use by people with diabetes and by healthcare providers.
We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006.
We launched our latest generation system, the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in 2018.
Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries.
To complement our direct sales efforts, we have entered into distribution arrangements in the United States, and certain countries in Africa, Asia, Europe, Latin America, and the Middle East, as well as Australia, Canada, and New Zealand that allow distributors to sell our products.
We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration.
Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices.
Eventually, we may apply our technological expertise to products beyond glucose monitoring.
Impact of COVID-19 Pandemic
During 2020, we were subject to challenging social and economic conditions created as a result of the novel strain of coronavirus, SARS-CoV-2 (“COVID-19”).
The resulting impact of the COVID-19 outbreak created various financial impacts to our operations as a result of taking necessary precautions for essential personnel to operate safely both in person as well as remotely.
Costs incurred include items like incremental payroll costs, consulting support, IT infrastructure and facilities-related costs.
As the result of the COVID-19 pandemic, we have made Dexcom CGM systems available for use in hospital settings and other healthcare facilities to assist frontline workers.
The extent of the impact of the COVID-19 outbreak on our operational and
financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers and our sales cycles, employee or industry events, and effect on our vendors, all of which are uncertain and cannot be predicted.
The COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we have begun to experience more pronounced disruptions in our operations.
We have experienced and may experience constrained supply or curtailed customer demand, including due to loss of coverage to our products, that could materially adversely impact our business, results of operations and overall financial performance in future periods.
We currently utilize third parties to, among other things, manufacture components and materials for our devices, and to provide services such as sterilization services and we purchase these materials and services from numerous suppliers worldwide.
The global COVID-19 pandemic has and may continue to have an adverse impact on our manufacturing and distribution capabilities.
Disruptions relating to the COVID-19 pandemic, including current shelter-in-place orders in the U.S. and other countries, could prevent employees, suppliers, distributors, and others from accessing manufacturing facilities and from transporting our products or the components required to manufacture our products.
For example, we have experienced some supply chain disruption due to the global restrictions resulting from the COVID-19 pandemic in the manufacture of our next-generation CGM product.
Further, worldwide supply chain disruption relating to the COVID-19 pandemic has resulted in product shortages that has and may continue to impact our ability to manufacture our devices.
As of the filing date of this Form 10-K, the extent to which COVID-19 may impact our financial condition or results of operations or guidance is uncertain.
The effect of the COVID-19 pandemic will not be fully reflected in our results of operations and overall financial performance until future periods.
We generate our revenue primarily from the sale of our Reusable Hardware and disposable sensors.
We generally recognize revenue when control is transferred to our customers in an amount that reflects the net consideration to which we expect to be entitled.
We exercise significant judgment when we determine the transaction price, including variable consideration adjustments.
Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix.
Variable consideration includes but is not limited to rebates, chargebacks, consideration payable to customers such as specialty distributor and wholesaler fees, product returns allowance, prompt payment discounts, and various other promotional or incentive arrangements.
Calculating certain of these items involves significant estimates and judgments based on sales or invoice data, contractual terms and historical utilization rates.
We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date.
If the actual amounts of consideration that we receive differ from our estimates, we would adjust our estimates and that would affect reported revenue in the period that such variances become known.
If any of these judgments were to change, it could cause a material increase or decrease in the amount of revenue we report in a particular period.
*Share-Based Compensation*
Share-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.
We value time-based Restricted Stock Units or RSUs at the date of grant using the intrinsic value method.
Certain RSUs granted to senior management vest based on the achievement of pre-established performance or market goals.
We estimate the fair value of performance-based RSUs at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met.
We update our assessment of the probability that the specified performance criteria will be achieved each quarter and adjust our estimate of the fair value of the performance-based RSUs if necessary.
The Monte Carlo methodology that we use to estimate the fair value of market-based RSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied.
An excerpt. Shown here: 40 of 76 rewritten, 40 of 87 added and 40 of 168 removed. The counts are complete. For every sentence, read Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS in the FY2021 filing and the FY2020 filing.
Page headers and footers: 2 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
7 rewritten, 0 added, 0 removed, 20 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
In order to reduce potential equity dilution, in connection with the issuance of the 2023 Notes we entered into the 2023 [added: Note] Hedge which entitles us to purchase shares of our common stock.
Upon conversion of the 2023 Notes, the 2023 [added: Note] Hedge is expected to reduce the equity dilution if the daily volume-weighted average price per share of our common stock exceeds the strike price of the hedge.
We also entered into warrant transactions with the counterparties of the 2023 [added: Note] Hedge entitling them to acquire shares of our common stock.
See Note 5 [added: “Debt”] to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the [added: Australian Dollar, the] British Pound, the [removed: Euro, and the] Canadian Dollar, [added: the Euro and the Malaysian Ringgit,] could adversely affect our financial results, including our revenues, revenue growth rates, gross margins, income and losses as well as assets and liabilities.
As of December 31, [removed: 2020,] [added: 2021,] we had foreign currency forward contracts outstanding with a notional amount of [removed: $48.0] [added: $40.0] million.
Derivative gains and losses are included in interest and other [removed: income,] [added: income (expense),] net in our consolidated statements of operations.
Item 1. BUSINESS
75 rewritten, 59 added, 56 removed, 502 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
We received approval from the United States [removed: (U.S.)] Food and Drug Administration, or FDA, and commercialized our first product in 2006.
The G7 [removed: carries] [added: is designed with the goal of carrying] forward many of the same features as our G6 CGM system and [removed: adds] [added: adding] several new or improved features, [removed: including][added: including:]
The G6 [removed: is] [added: was] the first type of CGM system permitted by the FDA to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management.
A patient’s glucose data can also be displayed on wearable devices, [added: like the Apple Watch® and Wear OS by Google devices.]
[removed: The G6 Pro has many of same features as the G6] and is intended for healthcare professionals to use with their patients ages two years and up.
The Dexcom Share remote monitoring system, offered for use with any current Dexcom system, uses an app on the patient’s [added: compatible] iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, or “followers,” who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have a wireless connection.
A patient’s glucose data can also be displayed on a patient’s or follower’s wearable device, such as the Apple Watch and Wear OS by Google devices, when used in conjunction with the patient’s or follower’s [added: compatible] iPhone or Android mobile [removed: device.*Data and Insulin Delivery Collaborations*][added: device.]
The general purpose of these development and commercial relationships is to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner’s insulin delivery [removed: device to receive and display glucose readings from our transmitter and, in some cases, use the glucose readings for semi-automated insulin delivery.]
In consideration of Verily’s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we have made upfront and incentive payments, and will make potential additional milestone payments [removed: of up to $275.0 million that may become due and payable by us upon the achievement of] [added: for] future product regulatory approval and [removed: revenue] [added: sales-based] milestones.
At our election, we may make these [removed: milestone] payments in shares of our common stock or cash.
See Note 2 [added: “Development and Other Agreements”] to the consolidated financial statements in Part II, Item 8 and Exhibit 10.31 of this Annual Report for a further description of the Restated Collaboration [removed: Agreement.][added: Agreement, including the number of shares of stock for milestone payments.]
The International Diabetes Federation, or IDF, estimates that in [removed: 2019, 463] [added: 2021, 537] million adults (aged 20-79) around the world had diabetes.
IDF estimates that by 2045, the worldwide incidence of people suffering from diabetes will reach [removed: 700] [added: 783] million.
According to the Centers for Disease Control and Prevention, or CDC, in its National Diabetes Statistics Report, [removed: 2020,] [added: 2022,] or the [removed: 2020] [added: 2022] CDC Report, crude estimates for the prevalence of diabetes in the United States as of [removed: 2018] [added: 2019] include [removed: 34] [added: 37.3] million people with diabetes, of which [removed: 26.9] [added: 28.7] million people have diagnosed diabetes.
The [removed: 2020] [added: 2022] CDC Report also lists diabetes as the seventh leading cause of death by disease in the United States, excluding comorbidities associated with the disease.
According to the IDF, there were an estimated [removed: 4.2] [added: 6.7] million deaths attributable to diabetes globally in [removed: 2019] [added: 2021] between the ages of 20 and 79 years.
The [removed: American Diabetes Association, or ADA, Fast Facts, revised in February 2020,] [added: report] states that diabetes is the primary cause of death for more than [removed: 83,000] [added: 87,000] Americans each year, and contributes to the death of more than [removed: 270,000] [added: 280,000] Americans annually.
According to the IDF, [removed: 2019] [added: 2021] expenditures attributable to diabetes were estimated to be [removed: $760] [added: $966] billion [removed: globally.][added: globally, an increase of 27% from their previous estimate in 2019.]
According to the [removed: 2020] [added: 2022] CDC Report, as of [removed: 2018] [added: 2019] there were an estimated [removed: 1.6] [added: 1.8] million adults and youth with diagnosed Type 1 diabetes in the United States.
We estimate that [removed: approximately] [added: between 5.0 and] 6.0 million [added: people with] Type 2 [removed: patients] [added: diabetes in the United States] must use insulin to manage their diabetes.
According to the CDC, as of [removed: 2016,] [added: 2017-2018,] approximately [removed: 18.5%] [added: 19.3%] of children and adolescents aged 2-19 years, or [removed: 13.7] [added: 14.4] million children, in the United States were obese.
In the future, we [removed: expect] [added: plan] to expand our product offering [added: and cleared/approved indications] to address people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting.
Also, our Share remote monitoring systems enable users of our current CGM systems to have their sensor glucose information remotely monitored by their family, friends or [added: other] designated recipient, or follower, by wirelessly transmitting data from the user’s smart phone to the cloud and then to the follower’s mobile device.
- Driving additional adoption through technology integration partnerships such as our current partnerships with Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes, The Ypsomed Group and [removed: others.][added: others globally.]
Our G6 system has labeling from the FDA and CE Mark permitting their use as a replacement for finger sticks for making therapeutic [removed: adjustments, although the G5 Mobile still requires two daily finger stick calibrations.][added: adjustments.]
We have built a direct sales organization in the United States, [removed: Canada] [added: Australia, Canada, New Zealand,] and [removed: certain] [added: some] countries in Europe to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring.
To complement our direct sales efforts, we have entered into distribution arrangements in the United States, [removed: Australia] and [removed: New Zealand, and] certain countries in Africa, Asia, Europe, Latin America, and the Middle [removed: East] [added: East, as well as Australia, Canada, and New Zealand] that allow distributors to sell our products.
As of December 31, [removed: 2020, our headquarters facilities] [added: 2021, we] had approximately [removed: 31,000] [added: 64,000] square feet of laboratory space and approximately [removed: 28,000] [added: 101,500] square feet of controlled environment rooms.
There are technical challenges to increasing manufacturing capacity, [removed: including FDA qualification of] [added: finding or enhancing] new manufacturing [added: facilities capable of meeting regulatory requirements, U.S. state licensure of manufacturing] facilities, equipment design and automation, material procurement, problems with production yields, and quality control and assurance.
Developing and maintaining commercial-scale manufacturing facilities has and will continue to require the investment of substantial additional funds and the hiring and [added: retention of additional management, quality assurance, quality control and technical personnel who have the necessary manufacturing experience.]
[removed: As of December 31, 2020, those single sources include] suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors.
We also have coverage under certain international markets and Medicaid coverage in [removed: 40] [added: about 44] states.
As of December 31, [removed: 2020,] [added: 2021,] the [removed: seven] [added: eight] largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of continuous glucose monitoring devices.
In addition, we have negotiated contracted rates with all [removed: seven] of those third-party payors for the purchase of our current CGM systems by their members.
For additional information on third-party reimbursement, please see our see Risk Factors entitled “*Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.”* [removed: *and*] [added: and] “*Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business*.”
We rely on a combination of patents, copyrights, trademarks, [removed: tradenames,] trade [added: names, trade] secrets, nondisclosure agreements and other measures to establish and protect our proprietary rights.
Our issued patents as of December 31, [removed: 2020] [added: 2021] are set to expire over a range of years, from [removed: 2021] [added: 2022] with respect to some of our earlier patents, to 2039, subject to any extensions.
[removed: Agreements with our employees also forbid] them from bringing the proprietary rights of third parties to us.
- *Think [removed: Big -*] [added: Big* –] We seek to expand global healthcare access for people with diabetes and actively work to increase access to our products.
If a previously unclassified new medical device does not qualify for the 510(k) pre-market notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class [removed: III.][added: III.Under FDA law, the *de novo* classification procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA.]
Product Candidates
The G6 Pro has many of same features as the G6
*Dexcom Real-Time API*
In July 2021, we received FDA 510(k) clearance for our Real-Time API, which expands connectivity and interoperability of the Dexcom CGM digital ecosystem.
Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health apps and devices.
*Dexcom ONE®*
In July 2021, we obtained CE Mark approval for our new Dexcom ONE CGM system, or Dexcom ONE, which we have launched in four countries: Bulgaria, Estonia, Latvia and Lithuania.
Dexcom ONE consists of three main components: a Dexcom ONE sensor, a Dexcom ONE transmitter, and a Dexcom ONE app as the display device for users with a compatible mobile device.
Dexcom ONE carries many of the same features as the G6, and is indicated for persons, including pregnant women, ages 2 years and older.
Like our other CGM systems, Dexcom ONE is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Data and Insulin Delivery Collaborations
device to receive and display glucose readings from our transmitter and, in some cases, use the glucose readings for semi-automated insulin delivery.
If we elect to make these milestone payments in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, adjusted for stock splits, dividends, and the like.
As of December 31, 2021, those single sources include
For additional information, please see our Risk Factor entitled, “*We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business*.” For supply risks related to COVID-19, see our Risk Factor entitled “*The outbreak of the SARS-Cov-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales*.”
Agreements with our employees also forbid
The FDA and the Food and Drug Branch of the
Violation of the Anti-Kickback Statute is a felony and conviction could result in the assessment of fines of up to $100,000 per violation or imprisonment for up to 10 years or both.
tam” actions.
covered entities), and business associates are subject to direct liability for violation of these provisions.
Other states are also seeking to regulate consumer privacy stringently, and both Virginia and Colorado signed comprehensive privacy legislation into law in 2021.
These laws (the Virginia Consumer Data Protection Act and the Colorado Privacy Act) are set to come into force in 2023 and a number of other state legislatures are actively considering passing similar consumer privacy laws, including those in New York and Washington.
*All diversity data is self-reported.
We capture ethnic diversity data in the United States only, comprised of the following categories: Black or African American, Hispanic or Latino, Asian, American Indian/Alaskan Native, Native Hawaiian or Other Pacific Islander, Two or More Races.
Our journey to create a more diverse, equitable and inclusive workplace continues.
We are proud of the additional ground we have gained in 2021 to advance our efforts and the external recognition received in *Forbes* magazine, landing on its *Best Employers for Women*, *Best Employers for Diversity* and *Best in State Employer* lists for the U.S. offices, and the Investors In People Silver Certification awarded to our Dexcom Philippines office.
We established diversity, equity, and inclusion, or DEI, as a corporate objective under our 2021 corporate goal related to the employee experience and commitment.
With expanded talent and diversity staff, we have evolved the DEI Leadership Council, or DLC, as a means for leaders to work closely together to advance the broader DEI strategy across the organization.
We have also added several more employee resource groups for our employees globally.
In 2021, we launched an interactive foundational training program on DEI for our managers, in each of Dexcom’s global locations.
To date, more than 70% of our global people leaders have completed this optional training.
In 2022, foundational DEI training will launch to all employees.
To continue to foster equity through our core talent processes, we rolled out a diversity snapshot data tool for our people leaders to establish a baseline understanding of the diversity of their teams and measure the effectiveness of DEI practices over time.
Our annual talent planning reviews have evolved to include discussion of function-specific DEI strengths and opportunities throughout each team.
In 2022, we plan to launch two pipeline development programs--one specifically aimed at developing top-performing diverse managers, and the other focused on fostering a diverse leadership pipeline.
In 2021, our company internship program doubled the number of women and ethnically diverse participants.
Ethnically diverse students accounted for nearly half of our 2021 internship class.
Our annual employee experience survey included a DEI index to help track our efforts on diversity, equity, inclusion, accessibility and belonging, which was favorable across all questions.The work we have done to date represents the beginning of our DEI journey.
To that end, we employ a mix of communication and engagement channels, including a global intranet and social network, and global
We have also deployed digital signage into our manufacturing and distribution areas to ensure that all our onsite employees remain connected to our mission and goals.
like the Apple Watch® and Wear OS by Google devices.
Global revenues associated with the sales of our previous commercial products, the Dexcom G4® Platinum CGM system and G5® Mobile CGM system, or G5 Mobile, amount to less than 10% of our revenue for the fiscal year ended 2020 and we anticipate phasing out these commercial products by the end of 2021.
The IDF estimates that expenditures attributable to diabetes will grow to $845 billion globally by 2045.
After a stabilization period with the G5 Mobile, the user is required to calibrate the
sensor with two measurements from a single-point finger stick device and the disposable sensor begins wirelessly transmitting the continuous glucose data at specific intervals to the handheld receiver or compatible mobile device.
Users are prompted by the receiver or mobile app, if using the G5 Mobile, to calibrate the system twice per day with finger stick measurements throughout the use period to ensure reliable operation.
Calibration may be accomplished by using any FDA cleared blood glucose meter.
Our Mesa, Arizona facility has approximately 14,000 square feet of laboratory space and approximately 33,000 square feet of controlled environment rooms.
retaining of additional management, quality assurance, quality control and technical personnel who have the necessary manufacturing experience.
The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the “Request for Evaluation of Automatic Class III Designation,” or the *de novo* classification procedure.
This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA.
Prior to the enactment of the Food and Drug Administration Safety and Innovation Act, or FDASIA, in July 2012, a medical device could only be eligible for *de novo* classification if the manufacturer first submitted a 510(k) pre-market notification and received a determination from the FDA that the device was not substantially equivalent.
FDASIA streamlined the *de novo* classification pathway by permitting (under Section 513(f)(2) of the FDCA) manufacturers to request *de novo* classification directly without first submitting a 510(k) pre-market notification to the FDA and receiving a not substantially equivalent determination.
FDASIA sets a review time for FDA of 120 days following receipt of the *de novo* application, but FDA does not always meet this timeline and has publicly only committed to a review goal of 150 days for 50% of applications.
If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device.
The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.
In December 2018, the FDA issued proposed regulations to govern the *de novo* classification process, which if finalized would further impact this path to market.
As an alternative to the *de novo* process, a company could also file a reclassification petition, or the FDA could initiate such a process, seeking to change the automatic Class III designation of a novel postamendment device under Section 513(f)(3) of the FDCA.
The FDA issued a final rule (to take effect March 17, 2019) to clarify the process where the FDA initiates such reclassification (issuance of a proposed reclassification order; optional panel consultation; and final reclassification order published in the Federal Register).
Our G4 PLATINUM and G5 Mobile systems (excluding associated Share System functionalities and mobile applications) were classified as devices requiring PMA approval.
After a PMA application is submitted and found to be sufficiently complete, the FDA begins an in-depth review of the submitted information.
During this review period, the FDA may request additional information or clarification of information already provided.
Also during the review period, an advisory panel of experts from outside the FDA may be
convened to review and evaluate the application and provide recommendations to the FDA.
In addition, the FDA generally will conduct a pre-approval inspection of the manufacturing facility to evaluate compliance with QSR, which requires manufacturers to implement and follow design, testing, control, documentation and other quality assurance procedures.
- our systems may not be safe or effective to the FDA’s satisfaction;
- the data from our pre-clinical studies and clinical trials may be insufficient to support approval;
- the manufacturing process or facilities we use may not meet applicable requirements; and
- changes in FDA approval policies or adoption of new regulations may require additional data.
These trials generally require submission of an application for an investigational device exemption, or IDE to the FDA.
The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound.
The IDE application must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a non-significant risk device and eligible for abbreviated IDE requirements.
Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards at the clinical trial sites.
The FDA’s approval of an IDE allows clinical testing to go forward, but does not bind the FDA to accept the results of the trial as sufficient to prove the product’s safety and efficacy, even if the trial meets its intended success criteria.
To obtain 510(k) clearance, we must submit a pre-market notification demonstrating that the software system is substantially equivalent to a previously cleared 510(k) device or a pre-amendment device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of a PMA application.
The FDA’s 510(k) clearance pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer.
After a medical device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a significant change in its intended use, requires a new 510(k) clearance.
In March 2018, we obtained marketing authorization for our G6 as an iCGM system for determining glucose (sugar) levels in children aged two and older and adults with diabetes, via the *de novo* process.
In addition, the Affordable Care Act amended federal law to provide that the
certain circumstances, may also be a business associate of another covered entity.
An excerpt. Shown here: 40 of 75 rewritten, 40 of 59 added and 40 of 56 removed. The counts are complete. For every sentence, read Item 1. BUSINESS in the FY2021 filing and the FY2020 filing.
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
Item 3. LEGAL PROCEEDINGS
1 rewritten, 2 added, 0 removed, 3 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
We do not believe we are party to any [added: other] currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition or results of operations.
During the fiscal year ended December 31, 2021, we and certain Abbott entities served complaints for patent infringement, validity and other patent related actions against each other in multiple jurisdictions, inside and outside the United States.
We intend to vigorously pursue our claims and defenses in these cases to protect our intellectual property and to defend against Abbott’s infringement allegations.
Cover and table of contents
27 rewritten, 36 added, 1 removed, 51 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
[removed: For] [added: For] the fiscal year ended [removed: December] [added: December] 31, [removed: 2020][added: 2021]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting [removed: company] [added: company,] or an emerging growth company.
As of June 30, [removed: 2020,] [added: 2021,] the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately [removed: $38.5] [added: $41.1] billion based on the closing sales price of [removed: $405.40] [added: $427.00] per share as reported on the Nasdaq Global Select Market.
| Class | | | | | | Outstanding at February [removed: 4, 2021] [added: 7, 2022] | | |
| Common stock, $0.001 par value per share | | | | | | [removed: 96,177,363] [added: 97,065,634] | | |
Portions of the registrant’s definitive proxy statement relating to its [removed: 2021] [added: 2022] Annual Meeting of Stockholders (the “Proxy Statement”) are incorporated by reference in Part III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers.
| | | | | | | [removed: Page] [added: Page] | | |
| [ITEM [removed: 1.](#i889b093251984bfb881a094ef59c54bd_13)] [added: 1.](#i15862298089b493198685c5d6204a6cb_13)] | | | [removed: [Business](#i889b093251984bfb881a094ef59c54bd_13)] [added: [Business](#i15862298089b493198685c5d6204a6cb_13)] | | | [removed: [3](#i889b093251984bfb881a094ef59c54bd_13)] [added: [5](#i15862298089b493198685c5d6204a6cb_13)] | | |
| [ITEM [removed: 1A.](#i889b093251984bfb881a094ef59c54bd_16)] [added: 1A.](#i15862298089b493198685c5d6204a6cb_19)] | | | [Risk [removed: Factors](#i889b093251984bfb881a094ef59c54bd_16)] [added: Factors](#i15862298089b493198685c5d6204a6cb_19)] | | | [removed: [23](#i889b093251984bfb881a094ef59c54bd_16)] [added: [25](#i15862298089b493198685c5d6204a6cb_19)] | | |
| [ITEM [removed: 1B.](#i889b093251984bfb881a094ef59c54bd_19)] [added: 1B.](#i15862298089b493198685c5d6204a6cb_22)] | | | [Unresolved Staff [removed: Comments](#i889b093251984bfb881a094ef59c54bd_19)] [added: Comments](#i15862298089b493198685c5d6204a6cb_22)] | | | [removed: [64](#i889b093251984bfb881a094ef59c54bd_19)] [added: [65](#i15862298089b493198685c5d6204a6cb_22)] | | |
| [ITEM [removed: 2.](#i889b093251984bfb881a094ef59c54bd_22)] [added: 2.](#i15862298089b493198685c5d6204a6cb_25)] | | | [removed: [Properties](#i889b093251984bfb881a094ef59c54bd_22)] [added: [Properties](#i15862298089b493198685c5d6204a6cb_25)] | | | [removed: [65](#i889b093251984bfb881a094ef59c54bd_22)] [added: [66](#i15862298089b493198685c5d6204a6cb_25)] | | |
| [ITEM [removed: 3.](#i889b093251984bfb881a094ef59c54bd_25)] [added: 3.](#i15862298089b493198685c5d6204a6cb_28)] | | | [Legal [removed: Proceedings](#i889b093251984bfb881a094ef59c54bd_25)] [added: Proceedings](#i15862298089b493198685c5d6204a6cb_28)] | | | [removed: [65](#i889b093251984bfb881a094ef59c54bd_25)] [added: [66](#i15862298089b493198685c5d6204a6cb_28)] | | |
| [ITEM [removed: 4.](#i889b093251984bfb881a094ef59c54bd_28)] [added: 4.](#i15862298089b493198685c5d6204a6cb_31)] | | | [Mine Safety [removed: Disclosures](#i889b093251984bfb881a094ef59c54bd_28)] [added: Disclosures](#i15862298089b493198685c5d6204a6cb_31)] | | | [removed: [65](#i889b093251984bfb881a094ef59c54bd_28)] [added: [66](#i15862298089b493198685c5d6204a6cb_31)] | | |
| [ITEM [removed: 5.](#i889b093251984bfb881a094ef59c54bd_34)] [added: 5.](#i15862298089b493198685c5d6204a6cb_37)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i889b093251984bfb881a094ef59c54bd_34)] [added: Securities](#i15862298089b493198685c5d6204a6cb_37)] | | | [removed: [66](#i889b093251984bfb881a094ef59c54bd_34)] [added: [67](#i15862298089b493198685c5d6204a6cb_37)] | | |
| [ITEM [removed: 7.](#i889b093251984bfb881a094ef59c54bd_40)] [added: 7.](#i15862298089b493198685c5d6204a6cb_46)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i889b093251984bfb881a094ef59c54bd_40)] [added: Operations](#i15862298089b493198685c5d6204a6cb_46)] | | | [removed: [68](#i889b093251984bfb881a094ef59c54bd_40)] [added: [69](#i15862298089b493198685c5d6204a6cb_46)] | | |
| [ITEM [removed: 7A.](#i889b093251984bfb881a094ef59c54bd_43)] [added: 7A.](#i15862298089b493198685c5d6204a6cb_49)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#i889b093251984bfb881a094ef59c54bd_43)] [added: Risk](#i15862298089b493198685c5d6204a6cb_49)] | | | [removed: [78](#i889b093251984bfb881a094ef59c54bd_43)] [added: [82](#i15862298089b493198685c5d6204a6cb_49)] | | |
| [ITEM [removed: 8.](#i889b093251984bfb881a094ef59c54bd_46)] [added: 8.](#i15862298089b493198685c5d6204a6cb_52)] | | | [removed: [Consolidated Financial] [added: [Financial] Statements and Supplementary [removed: Data](#i889b093251984bfb881a094ef59c54bd_46)] [added: Data](#i15862298089b493198685c5d6204a6cb_52)] | | | [removed: [78](#i889b093251984bfb881a094ef59c54bd_46)] [added: [83](#i15862298089b493198685c5d6204a6cb_52)] | | |
| [ITEM [removed: 9.](#i889b093251984bfb881a094ef59c54bd_49)] [added: 9.](#i15862298089b493198685c5d6204a6cb_55)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i889b093251984bfb881a094ef59c54bd_49)] [added: Disclosure](#i15862298089b493198685c5d6204a6cb_55)] | | | [removed: [79](#i889b093251984bfb881a094ef59c54bd_49)] [added: [83](#i15862298089b493198685c5d6204a6cb_55)] | | |
| [ITEM [removed: 9A.](#i889b093251984bfb881a094ef59c54bd_52)] [added: 9A.](#i15862298089b493198685c5d6204a6cb_58)] | | | [Controls and [removed: Procedures](#i889b093251984bfb881a094ef59c54bd_52)] [added: Procedures](#i15862298089b493198685c5d6204a6cb_58)] | | | [removed: [79](#i889b093251984bfb881a094ef59c54bd_52)] [added: [83](#i15862298089b493198685c5d6204a6cb_58)] | | |
| [ITEM [removed: 9B.](#i889b093251984bfb881a094ef59c54bd_55)] [added: 9B.](#i15862298089b493198685c5d6204a6cb_61)] | | | [Other [removed: Information](#i889b093251984bfb881a094ef59c54bd_55)] [added: Information](#i15862298089b493198685c5d6204a6cb_61)] | | | [removed: [81](#i889b093251984bfb881a094ef59c54bd_55)] [added: [86](#i15862298089b493198685c5d6204a6cb_61)] | | |
| [ITEM [removed: 10.](#i889b093251984bfb881a094ef59c54bd_61)] [added: 10.](#i15862298089b493198685c5d6204a6cb_67)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i889b093251984bfb881a094ef59c54bd_61)] [added: Governance](#i15862298089b493198685c5d6204a6cb_67)] | | | [removed: [81](#i889b093251984bfb881a094ef59c54bd_61)] [added: [86](#i15862298089b493198685c5d6204a6cb_67)] | | |
| [ITEM [removed: 11.](#i889b093251984bfb881a094ef59c54bd_64)] [added: 11.](#i15862298089b493198685c5d6204a6cb_70)] | | | [Executive [removed: Compensation](#i889b093251984bfb881a094ef59c54bd_64)] [added: Compensation](#i15862298089b493198685c5d6204a6cb_70)] | | | [removed: [81](#i889b093251984bfb881a094ef59c54bd_64)] [added: [86](#i15862298089b493198685c5d6204a6cb_70)] | | |
| [ITEM [removed: 12.](#i889b093251984bfb881a094ef59c54bd_67)] [added: 12.](#i15862298089b493198685c5d6204a6cb_73)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related [removed: Stockholders Matters](#i889b093251984bfb881a094ef59c54bd_67)] [added: Stockholder Matters](#i15862298089b493198685c5d6204a6cb_73)] | | | [removed: [81](#i889b093251984bfb881a094ef59c54bd_67)] [added: [86](#i15862298089b493198685c5d6204a6cb_73)] | | |
| [ITEM [removed: 13.](#i889b093251984bfb881a094ef59c54bd_70)] [added: 13.](#i15862298089b493198685c5d6204a6cb_76)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i889b093251984bfb881a094ef59c54bd_70)] [added: Independence](#i15862298089b493198685c5d6204a6cb_76)] | | | [removed: [81](#i889b093251984bfb881a094ef59c54bd_70)] [added: [86](#i15862298089b493198685c5d6204a6cb_76)] | | |
| [ITEM [removed: 14.](#i889b093251984bfb881a094ef59c54bd_73)] [added: 14.](#i15862298089b493198685c5d6204a6cb_79)] | | | [Principal Accountant Fees and [removed: Services](#i889b093251984bfb881a094ef59c54bd_73)] [added: Services](#i15862298089b493198685c5d6204a6cb_79)] | | | [removed: [81](#i889b093251984bfb881a094ef59c54bd_73)] [added: [86](#i15862298089b493198685c5d6204a6cb_79)] | | |
| [ITEM [removed: 15.](#i889b093251984bfb881a094ef59c54bd_79)] [added: 15.](#i15862298089b493198685c5d6204a6cb_85)] | | | [removed: [Exhibits, Financial] [added: [Exhibits](#i15862298089b493198685c5d6204a6cb_85) and [Financial] Statement [removed: Schedules](#i889b093251984bfb881a094ef59c54bd_79)] [added: Schedules](#i15862298089b493198685c5d6204a6cb_85)] | | | [removed: [82](#i889b093251984bfb881a094ef59c54bd_79)] [added: [87](#i15862298089b493198685c5d6204a6cb_85)] | | |
| [ITEM [removed: 16.](#i889b093251984bfb881a094ef59c54bd_82)] [added: 16.](#i15862298089b493198685c5d6204a6cb_88)] | | | [Form 10-K [removed: Summary](#i889b093251984bfb881a094ef59c54bd_82)] [added: Summary](#i15862298089b493198685c5d6204a6cb_88)] | | | [removed: [86](#i889b093251984bfb881a094ef59c54bd_82)] [added: [90](#i15862298089b493198685c5d6204a6cb_88)] | | |
| [ITEM 6.](#i15862298089b493198685c5d6204a6cb_40) | | | [\[Reserved\]](#i15862298089b493198685c5d6204a6cb_40) | | | [68](#i15862298089b493198685c5d6204a6cb_40) | | |
| [ITEM 9C.](#i15862298089b493198685c5d6204a6cb_1422) | | | [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#i15862298089b493198685c5d6204a6cb_1422) | | | [86](#i15862298089b493198685c5d6204a6cb_1422) | | |
| | | | [Signatures](#i15862298089b493198685c5d6204a6cb_91) | | | [91](#i15862298089b493198685c5d6204a6cb_91) | | |
| Summary of Risk Factors | | |
The below summary of risk factors provides an overview of many of the risks we are exposed to in the normal course of our business activities.
As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading “Risk Factors,” as well as elsewhere in this Annual Report on Form 10-K.
Additional risks, beyond those summarized below or discussed elsewhere in this Annual Report on Form 10-K, may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate.
Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with the following:
- If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
- We are subject to cost-containment efforts by our payors that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.
- Although many third-party payors have adopted some form of coverage policy on continuous glucose monitoring devices, our products do not always have some form of coverage, including simple broad-based contractual coverage, with third-party payors and we frequently experience administrative challenges in obtaining reimbursement for our customers.
If we are unable to obtain adequately broad reimbursement at acceptable prices for our products or any future products from third-party payors, our revenue may be negatively impacted.
- The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.
- Our products may not achieve or maintain market acceptance.
- If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.
- Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.
- We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.
- If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.
- We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.
- The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
- We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.
- We have incurred significant losses in the past and may incur losses in the future.
- We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters.
Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
- Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.
- We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.
- Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.
- Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.
- If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.
- We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief.
We may also be subject to other claims or suits.
- Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.
- We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.
- We could become the subject of governmental investigations, claims and litigation.
- Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.
- We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.
| [ITEM 6.](#i889b093251984bfb881a094ef59c54bd_37) | | | [Selected Financial Data](#i889b093251984bfb881a094ef59c54bd_37) | | | [68](#i889b093251984bfb881a094ef59c54bd_37) | | |
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
Item 2. PROPERTIES
4 rewritten, 0 added, 0 removed, 6 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
The following [added: table] lists those properties that we believe are material to our business.
| San Diego, CA | | | | | | [removed: 633,100] [added: 698,000] | | | | | | Laboratory, Manufacturing, Research and Development, Warehouse, General and Administrative, Sales and Marketing | | | | | | 2028 (1) | | |
(1) Excludes renewals that would be at our option to extend the term of a lease for approximately 351,400 square feet of space expiring in 2023 for two additional three to five-year [removed: terms] [added: terms, renewals that would be at our option to extend the term of a lease for approximately 148,400 square feet of space expiring in 2028 for one additional five-year term,] and also excludes renewals that would be at our option to extend the term of a lease for approximately [removed: 126,700] [added: 92,500] square feet of space expiring in 2028 for [removed: one] [added: two] additional five-year [removed: term.][added: terms.]
We also lease various administrative, warehouse and customer support real properties throughout the world including [removed: the U.S., Canada, Germany, the Philippines, Switzerland, Lithuania] [added: North America, Europe,] and the [removed: United Kingdom.][added: Asia-Pacific region.]
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
14 rewritten, 3 added, 3 removed, 5 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
[removed: *Market] [added: Market] Information for Common [removed: Stock*][added: Stock]
[removed: Dexcom’s] [added: Our] common stock is traded on the Nasdaq Global Select Market under the symbol “DXCM.”
[removed: *Stockholders*][added: Stockholders]
We had fewer than 40 stockholders of record as of December 31, [removed: 2020.][added: 2021.]
[removed: *Dividend Policy*][added: Dividend Policy]
[removed: *Recent] [added: Recent] Sales of Unregistered [removed: Securities*][added: Securities]
There were no unregistered sales of equity securities which have not been previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K during the [added: fiscal] year ended December 31, [removed: 2020.][added: 2021.]
[removed: *Purchases] [added: Purchases] of Equity Securities by the Issuer and Affiliated [removed: Purchasers*][added: Purchasers]
Neither we nor any affiliated purchaser repurchased any of our equity securities during the [added: fiscal] year ended December 31, [removed: 2020.][added: 2021.]
[removed: *Company] [added: Company] Stock Price [removed: Performance*][added: Performance]
The graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the Nasdaq Composite Index and the Nasdaq Medical Equipment Index over the five-year period ended December 31, [removed: 2020.][added: 2021.]
The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December 31, [removed: 2015] [added: 2016] and that all dividends were reinvested.
* $100 invested on December 31, [removed: 2015] [added: 2016] in stock or index, including reinvestment of any dividends.
| | | | | | | December 31, [removed: 2015] [added: 2016] | | | | | | December 31, [removed: 2016] [added: 2017] | | | | | | December 31, [removed: 2017] [added: 2018] | | | | | | December 31, [removed: 2018] [added: 2019] | | | | | | December 31, [removed: 2019] [added: 2020] | | | | | | December 31, [removed: 2020] [added: 2021] | | |
| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 96.13 | | | | | $ | 200.67 | | | | | $ | 366.40 | | | | | $ | 619.30 | | | | | $ | 899.41 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 129.64 | | | | | $ | 125.96 | | | | | $ | 172.17 | | | | | $ | 249.51 | | | | | $ | 304.85 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 145.08 | | | | | $ | 161.91 | | | | | $ | 196.50 | | | | | $ | 281.91 | | | | | $ | 332.54 | |
| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 72.89 | | | | | $ | 70.07 | | | | | $ | 146.28 | | | | | $ | 267.08 | | | | | $ | 451.43 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 108.87 | | | | | $ | 141.13 | | | | | $ | 137.12 | | | | | $ | 187.44 | | | | | $ | 271.64 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 106.07 | | | | | $ | 153.41 | | | | | $ | 171.99 | | | | | $ | 209.03 | | | | | $ | 300.10 | |
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
Item 6. [RESERVED]
0 rewritten, 0 added, 1 removed, 0 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
Omitted pursuant to amendments to Item 301 of Regulation S-K effective February 10, 2021.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
1 rewritten, 2 added, 0 removed, 0 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
The information required is set forth under “Report of Independent Registered Public Accounting Firm,” “Consolidated Balance Sheets,” “Consolidated Statements of Operations,” “ Consolidated Statements of Comprehensive [removed: Income (Loss),”] [added: Income,”] “Consolidated Statements of Stockholders’ Equity,” “Consolidated Statements of Cash Flows” and “Notes to Consolidated Financial Statements” on pages [removed: [F-2](#i889b093251984bfb881a094ef59c54bd_112)] [added: [F-2](#i15862298089b493198685c5d6204a6cb_115)] to [removed: [F-42](#i889b093251984bfb881a094ef59c54bd_169)] [added: [F-4](#i15862298089b493198685c5d6204a6cb_163)[0](#i15862298089b493198685c5d6204a6cb_163)] of this Annual Report and is incorporated into this Item 8 by reference.
The report of Dexcom’s independent registered public accounting firm (PCAOB ID:42) with respect to the above-referenced financial statements and their report on internal control over financial reporting are included in Item 8 and Item 9A of this Form 10-K.
Their consent appears as Exhibit 23.01 of this Form 10-K.
Item 9A. CONTROLS AND PROCEDURES
8 rewritten, 2 added, 1 removed, 38 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
Regulations under the Securities Exchange Act of 1934 require public companies to maintain “disclosure controls and procedures,” which are defined to mean a company’s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and timely communicated to management, including our Chief Executive Officer and Chief Financial Officer, recorded, processed, [removed: summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.]
Based on their evaluation as of December 31, [removed: 2020,] [added: 2021,] our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date for this purpose.
Our management, with the participation of the Chief Executive and Chief Financial Officers, assessed the effectiveness of our internal control over financial reporting as of December 31, [removed: 2020.][added: 2021.]
Based on this assessment, our management, with the participation of the Chief Executive and Chief Financial Officers, believes that, as of December 31, [removed: 2020,] [added: 2021,] our internal control over financial reporting is effective based on those criteria.
The effectiveness of our internal control over financial reporting as of December 31, [removed: 2020] [added: 2021] has been audited by Ernst & Young LLP an Independent Registered Public Accounting Firm, as stated in their report which is included herein.
We have audited DexCom, Inc.’s internal control over financial reporting as of December 31, [removed: 2020,] [added: 2021,] based on criteria established in Internal [removed: Control Integrated] [added: Control—Integrated] Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO criteria).
In our opinion, DexCom, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2020,] [added: 2021,] based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of DexCom, Inc. as of December 31, [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] the related consolidated statements of operations, comprehensive [removed: income (loss),] [added: income,] stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2020,] [added: 2021,] and the related notes and financial statement schedule listed in the Index at Item 15(a) and our report dated February [removed: 11, 2021] [added: 14, 2022] expressed an unqualified opinion thereon.
summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
February 14, 2022
February 11, 2021
Item 9B. OTHER INFORMATION
0 rewritten, 0 added, 1 removed, 1 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
PART III
Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
0 rewritten, 2 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2021 item · filed February 14, 2022
None.
PART III
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
2 rewritten, 0 added, 0 removed, 5 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
The information concerning our directors required by this Item is incorporated by reference to the section in [removed: our] [added: the] Proxy Statement entitled “Proposal No. 1 – Election of Directors.”
The information concerning our executive officers required by this Item is incorporated by reference to the section in [removed: our] [added: the] Proxy Statement entitled “Executive Officers.”
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
The information concerning certain relationships and related transactions required by [removed: the] [added: this] Item is incorporated by reference to the section in [removed: our] [added: the] Proxy Statement entitled “Certain Transactions.”
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
The information concerning principal accountant fees and services required by this Item is incorporated by reference to the section in [removed: our] [added: the] Proxy Statement entitled “Ratification of Selection of Independent Registered Public Accounting Firm.”
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
49 rewritten, 9 added, 12 removed, 29 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
For the three fiscal years ended December 31, [removed: 2020,] [added: 2021,] Schedule II – Valuation and Qualifying Accounts.
| [removed: [3.01](http://www.sec.gov/Archives/edgar/data/1093557/000104746905005246/a2152786zex-3_03.htm)] [added: [4.01](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] | | | | | | [removed: [Registrant’s Restated Certificate] [added: [Form] of [removed: Incorporation.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905005246/a2152786zex-3_03.htm)] [added: Specimen Certificate for Registrant’s common stock](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] | | | | | | S-1/A | | | | | | 333-122454 | | | | | | March [removed: 3,] [added: 24,] 2005 | | | | | | [removed: 3.03] [added: 4.01] | | | | | | | | | | | |
| [removed: [4.0](http://www.sec.gov/Archives/edgar/data/1093557/000119312518340482/d667223dex41.htm)[2](http://www.sec.gov/Archives/edgar/data/1093557/000119312518340482/d667223dex41.htm)] [added: [4.02](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] | | | | | | [Indenture, dated as of November 30, [removed: 201](http://www.sec.gov/Archives/edgar/data/1093557/000119312518340482/d667223dex41.htm)[8](http://www.sec.gov/Archives/edgar/data/1093557/000119312518340482/d667223dex41.htm)[,] [added: 2018,] between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due [removed: 2023)](http://www.sec.gov/Archives/edgar/data/1093557/000119312518340482/d667223dex41.htm)] [added: 2023)](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | December 3, 2018 | | | | | | 4.1 | | | | | | | | | | | |
| [removed: [4.03](http://www.sec.gov/Archives/edgar/data/1093557/000119312520143408/d926678dex41.htm)] [added: [4.03](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] | | | | | | [Indenture, dated as of May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due [removed: 2025)](http://www.sec.gov/Archives/edgar/data/1093557/000119312520143408/d926678dex41.htm)] [added: 2025)](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 15, 2020 | | | | | | 4.1 | | | | | | | | | | | |
| [removed: [4.04](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex404securitie.htm)] [added: [4.04](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex404securitie.htm)] | | | | | | [Description of Securities Registered Under Section 12 of the Exchange [removed: Act.](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex404securitie.htm)] [added: Act.](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex404securitie.htm)] | | | | | | [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 11, 2021] | | | | | | [added: 4.04] | | | | | | [removed: X] | | | | | |
| [removed: [10.01](https://www.sec.gov/Archives/edgar/data/1093557/000110465906023702/a06-8554_1ex99d01.htm)] [added: [10.01](http://www.sec.gov/Archives/edgar/data/1093557/000110465906023702/a06-8554_1ex99d01.htm)] | | | | | | [Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P.](http://www.sec.gov/Archives/edgar/data/1093557/000110465906023702/a06-8554_1ex99d01.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | April 7, 2006 | | | | | | 99.01 | | | | | | | | | | | |
| [removed: [10.02](https://www.sec.gov/Archives/edgar/data/1093557/000110465906025014/a06-8874_1ex99d01.htm)] [added: [10.04](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] | | | | | | [Offer letter between DexCom, Inc. and [removed: Steven R. Pacelli] [added: Kevin Sayer] dated [removed: April 10, 2006.*](http://www.sec.gov/Archives/edgar/data/1093557/000110465906025014/a06-8874_1ex99d01.htm)] [added: May 3, 2011.*](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] | | | | | | [removed: 8-K] [added: 10-Q] | | | | | | 000-51222 | | | | | | [removed: April 13, 2006] [added: August 3, 2011] | | | | | | [removed: 99.01] [added: 10.28] | | | | | | | | | | | |
| [removed: [10.04](https://www.sec.gov/Archives/edgar/data/1093557/000119312509162218/dex1023.htm)] [added: [10.16](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1041.htm)] | | | | | | [removed: [Non-Exclusive] [added: [Amendment to Non-Exclusive] Distribution [removed: Agreement,] [added: Agreement dated April 30, 2016 by and] between RGH Enterprises, Inc. [added: d/b/a Cardinal Health at Home] and DexCom, [removed: Inc., dated April 30, 2008.](http://www.sec.gov/Archives/edgar/data/1093557/000119312509162218/dex1023.htm)] [added: Inc. ](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1041.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August [removed: 3, 2009] [added: 2, 2016] | | | | | | [removed: 10.23] [added: 10.41] | | | | | | | | | | | |
| [removed: [10.06](https://www.sec.gov/Archives/edgar/data/1093557/000119312510248085/dex1027.htm)] [added: [10.02](http://www.sec.gov/Archives/edgar/data/1093557/000119312510248085/dex1027.htm)] | | | | | | [First Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated August 18, 2010.](http://www.sec.gov/Archives/edgar/data/1093557/000119312510248085/dex1027.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | November 4, 2010 | | | | | | 10.27 | | | | | | | | | | | |
| [removed: [10.07](https://www.sec.gov/Archives/edgar/data/1093557/000119312511179874/dex1026.htm)] [added: [10.03](http://www.sec.gov/Archives/edgar/data/1093557/000119312511179874/dex1026.htm)] | | | | | | [Amendment Number One to Non-Exclusive Distribution Agreement, between RGH Enterprises, Inc. and DexCom, Inc., dated March 29, 2011.](http://www.sec.gov/Archives/edgar/data/1093557/000119312511179874/dex1026.htm) | | | | | | 10-Q/A | | | | | | 000-51222 | | | | | | July 1, 2011 | | | | | | 10.26 | | | | | | | | | | | |
| [removed: [10.08](https://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: [10.15](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016ex1040.htm)] | | | | | | [removed: [Offer letter] [added: [Standard Form of Agreement dated May 2, 2016, by and] between DexCom, Inc. and [removed: Kevin Sayer dated May 3, 2011.*](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: Skanska USA Building Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016ex1040.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August [removed: 3, 2011] [added: 2, 2016] | | | | | | [removed: 10.28] [added: 10.40] | | | | | | | | | | | |
| [removed: [10.09](https://www.sec.gov/Archives/edgar/data/1093557/000109355713000036/dxcm03312013ex1027.htm)] [added: [10.05](http://www.sec.gov/Archives/edgar/data/1093557/000109355713000036/dxcm03312013ex1027.htm)] | | | | | | [Amendment Number Two to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated March 28, 2013.](http://www.sec.gov/Archives/edgar/data/1093557/000109355713000036/dxcm03312013ex1027.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | May 1, 2013 | | | | | | 10.27 | | | | | | | | | | | |
| [removed: [10.10](https://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1028.htm)] [added: [10.06](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1028.htm)] | | | | | | [Amendment Number Three to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated December 4, 2013.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1028.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 20, 2014 | | | | | | 10.28 | | | | | | | | | | | |
| [removed: [10.11](https://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm)] [added: [10.07](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm)] | | | | | | [Non-Exclusive Distribution Agreement between [removed: Dex](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm)[C](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm)[om,] [added: DexCom,] Inc. and Diabetes Specialty Center, LLC dated October 12, 2009, as amended on September 30, 2010, October 11, 2011, November 14, 2012 and November 1, 2013.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 20, 2014 | | | | | | 10.29 | | | | | | | | | | | |
| [removed: [10.12](https://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1031.htm)] [added: [10.08](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1032.htm)] | | | | | | [removed: [Settlement and License] [added: [Amendment No. 5 to Non-Exclusive Distribution] Agreement [removed: by and among Abbott Diabetes Care,] [added: between DexCom,] Inc. and [removed: DexCom, Inc.,] [added: Diabetes Specialty Center, LLC,] dated [removed: July 2, 2014.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1031.htm)] [added: March 14, 2014.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1032.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 6, 2014 | | | | | | [removed: 10.31] [added: 10.32] | | | | | | | | | | | |
| [removed: [10.14](https://www.sec.gov/Archives/edgar/data/1093557/000109355715000040/dxcm-12312014ex1033.htm)] [added: [10.09](http://www.sec.gov/Archives/edgar/data/1093557/000109355715000040/dxcm-12312014ex1033.htm)] | | | | | | [Second Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated October 1, 2014.](http://www.sec.gov/Archives/edgar/data/1093557/000109355715000040/dxcm-12312014ex1033.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 25, 2015 | | | | | | 10.32 | | | | | | | | | | | |
| [removed: [10.15](https://www.sec.gov/Archives/edgar/data/1093557/000119312515127507/d878103ddef14a.htm)] [added: [10.10](http://www.sec.gov/Archives/edgar/data/1093557/000119312515127507/d878103ddef14a.htm#toc878103_89)] | | | | | | [2015 Employee Stock Purchase [removed: Plan](http://www.sec.gov/Archives/edgar/data/1093557/000119312515127507/d878103ddef14a.htm)] [added: Plan](http://www.sec.gov/Archives/edgar/data/1093557/000119312515127507/d878103ddef14a.htm#toc878103_89)] | | | | | | DEF 14A | | | | | | 000-51222 | | | | | | April 13, 2015 | | | | | | Appendix [removed: A] [added: B] | | | | | | | | | | | |
| [removed: [10.16](https://www.sec.gov/Archives/edgar/data/1093557/000109355715000171/exhibit104.htm)] [added: [10.11](http://www.sec.gov/Archives/edgar/data/1093557/000109355715000171/exhibit104.htm)] | | | | | | [Form of Subscription Agreement under 2015 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1093557/000109355715000171/exhibit104.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 2, 2015 | | | | | | 10.4 | | | | | | | | | | | |
| [removed: [10.17](https://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] [added: [10.12](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] | | | | | | [Sublease between DexCom, Inc. and Entropic Communications, LLC dated February 1, 2016.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | April 27, 2016 | | | | | | 10.36 | | | | | | | | | | | |
| [removed: [10.18](https://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1037.htm)] [added: [10.13](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1037.htm)] | | | | | | [Amended and Restated Non-Exclusive Distribution Agreement with Byram Healthcare dated February 1, 2016.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1037.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | April 27, 2016 | | | | | | 10.37 | | | | | | | | | | | |
| [removed: [10.19](https://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm)] [added: [10.14](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm)] | | | | | | [Industrial Net Lease, Broadway dated April 28, 2016, by and between PRA/LB, L.L.C. and DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 2, 2016 | | | | | | 10.39 | | | | | | | | | | | |
| [removed: [10.20](https://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016ex1040.htm)] [added: [10.20](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm06302017ex1047.htm)] | | | | | | [Standard Form of Agreement dated May [removed: 2, 2016,] [added: 1, 2017,] by and between DexCom, Inc. and Skanska USA Building [removed: Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016ex1040.htm)] [added: Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm06302017ex1047.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August [removed: 2, 2016] [added: 1, 2017] | | | | | | [removed: 10.40] [added: 10.47] | | | | | | | | | | | |
| [removed: [10.22](https://www.sec.gov/Archives/edgar/data/1093557/000109355717000048/dxcm12312016ex1042.htm)] [added: [10.17](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000048/dxcm12312016ex1042.htm)] | | | | | | [Amendment No. 1 to Collaboration and License Agreement dated October 25, 2016 by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC).](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000048/dxcm12312016ex1042.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 28, 2017 | | | | | | 10.42 | | | | | | | | | | | |
| [removed: [10.23](https://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex102.htm)] [added: [10.18](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex102.htm)] | | | | | | [Severance and Change in Control Plan.](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex102.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 6, 2017 | | | | | | [removed: 10.20] [added: 10.2] | | | | | | | | | | | |
| [removed: [10.24](https://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex103.htm)] [added: [10.19](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex103.htm)] | | | | | | [Form of Participation Agreement to the Severance and Change in Control Plan.](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex103.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 6, 2017 | | | | | | [removed: 10.30] [added: 10.3] | | | | | | | | | | | |
| [removed: [10.25](https://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1046.htm)] [added: [10.25](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1061.htm)] | | | | | | [removed: [First Amendment to] [added: [Amended and Restated] Credit Agreement dated [removed: June 17, 2016] [added: December 19, 2018] by and among DexCom, Inc., [removed: the Lenders,] [added: Bank of America, Silicon Valley Bank] and [added: Union Bank, and] JPMorgan Chase Bank, as Administrative [removed: Agent.](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1046.htm)] [added: Agent.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1061.htm)] | | | | | | [removed: 10-Q] [added: 10-K] | | | | | | 000-51222 | | | | | | [removed: August 1, 2017] [added: February 21, 2019] | | | | | | [removed: 10.46] [added: 10.61] | | | | | | | | | | | |
| [removed: [10.26](https://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm06302017ex1047.htm)] [added: [10.21](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1043.htm)] | | | | | | [removed: [Standard Form] [added: [Form] of [removed: Agreement dated May 1, 2017, by and between DexCom, Inc. and Skanska USA Building Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm06302017ex1047.htm)] [added: Indemnity Agreement](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1043.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 1, 2017 | | | | | | [removed: 10.47] [added: 10.43] | | | | | | | | | | | |
| [removed: [10.29](https://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1051.htm)] [added: [10.22](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1051.htm)] | | | | | | [Form of RSU Grant Agreement 2015 Plan Global Double Trigger](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1051.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 27, 2018 | | | | | | 10.51 | | | | | | | | | | | |
| [removed: [10.30](https://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1052.htm)] [added: [10.23](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1052.htm)] | | | | | | [Form of RSU Grant Agreement 2015 Plan Global General](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1052.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 27, 2018 | | | | | | 10.52 | | | | | | | | | | | |
| [removed: [10.31](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1060.htm)] [added: [10.24](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1060.htm)] | | | | | | [Amended and Restated Collaboration and License Agreement dated November 20, 2018 by and between DexCom, Inc., Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1060.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 21, 2019 | | | | | | 10.60 | | | | | | | | | | | |
| [removed: [10.32](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1061.htm)] [added: [10.39](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] | | | | | | [removed: [Amended] [added: [Second Amended] and Restated Credit Agreement [removed: dated December 19, 2018 by] [added: dated](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) [October 13, 202](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)[1](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) [by] and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative [removed: Agent.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1061.htm)] [added: Agent.](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February [removed: 21, 2019] [added: 14, 2022] | | | | | | [removed: 10.61] | | | | | | [added: X] | | | | | |
| [removed: [10.33](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000103/dxcm-2019xdef14a.htm#sc05aea42c3974fe2883a04a695d7a7ff)] [added: [10.26](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000103/dxcm-2019xdef14a.htm#sc05aea42c3974fe2883a04a695d7a7ff)] | | | | | | [Amended and Restated 2015 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000103/dxcm-2019xdef14a.htm#sc05aea42c3974fe2883a04a695d7a7ff) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 4, 2019 | | | | | | 10.01 | | | | | | | | | | | |
| [removed: [10.34](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: [10.27](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] | | | | | | [Executive Deferred Compensation Plan](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 4, 2019 | | | | | | 10.02 | | | | | | | | | | | |
| [removed: [10.35](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1036.htm)] [added: [10.28](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1036.htm)] | | | | | | [Form of RSU Grant Agreement 2015 Plan (Board Members - Annual [removed: Grant)](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1036.htm)] [added: Grant)](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1036.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.36 | | | | | | | | | | | |
| [removed: [10.36](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1037.htm)] [added: [10.29](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1037.htm)] | | | | | | [Form of RSU Grant Agreement 2015 Plan (Board Members - Incoming [removed: Grant)](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1037.htm)] [added: Grant)](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1037.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.37 | | | | | | | | | | | |
| [removed: [10.37](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1038.htm)] [added: [10.30](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1038.htm)] | | | | | | [Distribution Services Agreement dated November 7, 2015 between DexCom, Inc. and AmerisourceBergen Drug [removed: Corporation.](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1038.htm)] [added: Corporation.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1038.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.38 | | | | | | | | | | | |
| [removed: [10.38](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm)] [added: [10.31](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm)] | | | | | | [Amendment to the Distribution Services Agreement between [removed: Dex](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm)[C](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm)[om] [added: DexCom] Inc. and AmerisourceBergen Drug [removed: Corporation.](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm)] [added: Corporation.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.39 | | | | | | | | | | | |
| [removed: [10.39](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] [added: [10.32](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | [Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, [removed: 2019.](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] [added: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.40 | | | | | | | | | | | |
| [removed: [10.40](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1041.htm)] [added: [10.33](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1041.htm)] | | | | | | [Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, [removed: 2019.](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1041.htm)] [added: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1041.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.41 | | | | | | | | | | | |
| [removed: [10.41](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1042.htm)] [added: [10.34](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1042.htm)] | | | | | | [Fifth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated October 21, [removed: 2019.](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1042.htm)] [added: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1042.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.42 | | | | | | | | | | | |
| [3.01](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex31.htm) | | | | | | [Restated Certificate of Incorporation of Dexcom, Inc.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex31.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 21, 2021 | | | | | | 3.1 | | | | | | | | | | | |
| [3.02](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm) | | | | | | [Amended and Restated Bylaws of DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 21, 2021 | | | | | | 3.3 | | | | | | | | | | | |
| [10.38](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm) | | | | | | [DexCom Incentive Bonus Plan](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | March 17, 2021 | | | | | | 10.1 | | | | | | | | | | | |
| [10.40](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1040sixthame.htm) | | | | | | [Sixth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated May 25, 2021](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1040sixthame.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.41](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1041tenantes.htm) | | | | | | [Tenant Estoppel Certificate - Sequence](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1041tenantes.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.42](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex104210455pac.htm) | | | | | | [Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated January 31, 2020](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex104210455pac.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.43](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1043firstame.htm) | | | | | | [First Amendment to Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated November 17, 2020](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1043firstame.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.44](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1044tenantes.htm) | | | | | | [Tenant Estoppel Certificate - Pacific Center](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1044tenantes.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.45](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1045tenantsa.htm) | | | | | | [Tenant’s Acceptance of Possession - Pacific Center](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1045tenantsa.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [3.02](http://www.sec.gov/Archives/edgar/data/1093557/000119312517130445/d348320ddef14a.htm) | | | | | | [Amendment No. 1 to Registrant’s Restated Certificate of Incorporation.](http://www.sec.gov/Archives/edgar/data/1093557/000119312517130445/d348320ddef14a.htm) | | | | | | DEF 14 A | | | | | | 000-51222 | | | | | | April 20, 2017 | | | | | | Appendix B | | | | | | | | | | | |
| [3.03](http://www.sec.gov/Archives/edgar/data/1093557/000119312520242202/d847783dex31.htm) | | | | | | [Registrant’s Amended and Restated Bylaws.](http://www.sec.gov/Archives/edgar/data/1093557/000119312520242202/d847783dex31.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | September 9, 2020 | | | | | | 3.1 | | | | | | | | | | | |
| [4.01](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) | | | | | | [Form of Specimen Certificate for Registrant’s common stock.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) | | | | | | S-1/A | | | | | | 333-122454 | | | | | | March 24, 2005 | | | | | | 4.01 | | | | | | | | | | | |
| [10.03](https://www.sec.gov/Archives/edgar/data/1093557/000119312509046182/dex1020.htm) | | | | | | [Form of Amended and Restated Executive Change of Control & Severance Agreement.*](http://www.sec.gov/Archives/edgar/data/1093557/000119312509046182/dex1020.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | March 5, 2009 | | | | | | 10.20 | | | | | | | | | | | |
| [10.05](https://www.sec.gov/Archives/edgar/data/1093557/000119312510051468/dex1025.htm) | | | | | | [Amended and Restated Development, Manufacturing, Licensing and Supply Agreement, between DSM PTG, Inc. and DexCom, Inc., dated February 19, 2010.](http://www.sec.gov/Archives/edgar/data/1093557/000119312510051468/dex1025.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | March 9, 2010 | | | | | | 10.25 | | | | | | | | | | | |
| [10.13](https://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1032.htm) | | | | | | [Amendment No. 5 to Non-Exclusive Distribution Agreement between DexCom, Inc. and Diabetes Specialty Center, LLC, dated March 14, 2014.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1032.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 6, 2014 | | | | | | 10.32 | | | | | | | | | | | |
| [10.21](https://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1041.htm) | | | | | | [Amendment to Non-Exclusive Distribution Agreement dated April 30, 2016 by and between RGH Enterprises, Inc. d/b/a Cardinal Health at Home and DexCom, Inc. ](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1041.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 2, 2016 | | | | | | 10.41 | | | | | | | | | | | |
| [10.27](https://www.sec.gov/Archives/edgar/data/1093557/000109355717000168/dxcm080117ex101.htm) | | | | | | [Offer Letter for Quentin S. Blackford dated July 28, 2017. *](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000168/dxcm080117ex101.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | August 1, 2017 | | | | | | 10.10 | | | | | | | | | | | |
| [10.28](https://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1043.htm) | | | | | | [Form of Indemnity Agreement](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1043.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 1, 2017 | | | | | | 10.43 | | | | | | | | | | | |
| [10.42](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000217/dxcm6302020exhibit1001.htm) | | | | | | [First Amendment to Amended and Restated Credit Agreement by and among DexCom, Inc., the Lenders, and JPMorgan Chase Bank as Administrative Agent, dated May 11, 2020](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000217/dxcm6302020exhibit1001.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | July 28, 2020 | | | | | | 10.01 | | | | | | | | | | | |
| [10.46](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020exhibit1046moy.htm) | | | | | | [Incentive Agreement between Dex](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020exhibit1046moy.htm)[C](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020exhibit1046moy.htm)[om, Inc. and Jeffrey Moy dated April 28, 2020](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020exhibit1046moy.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.47](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1047doubleda.htm) | | | | | | [Transition and Consulting Agreement between Dex](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1047doubleda.htm)[C](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1047doubleda.htm)[om, Inc. and Richard B.](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1047doubleda.htm) [Doubleday dated December 10, 2020](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1047doubleda.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
An excerpt. Shown here: 40 of 49 rewritten, all 9 added and all 12 removed. The counts are complete. For every sentence, read Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES in the FY2021 filing and the FY2020 filing.
Item 16. FORM 10-K SUMMARY
526 rewritten, 164 added, 183 removed, 544 unchanged
Read the full itemFY2021 item · filed February 14, 2022FY2020 item · filed February 11, 2021
[removed: KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin Sayer and Quentin Blackford,] [added: Sylvain,] jointly and severally, his attorneys-in-fact, each with the power of substitution, for him in any and all capacities, to sign any amendments to this Report on Form 10-K and to file same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.
| [removed: /S/] [added: /s/] KEVIN R. SAYER | | | | | | Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| [removed: /S/] [added: /s/] MARK [added: G.] FOLETTA | | | | | | Lead Independent Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| Mark [added: G.] Foletta | | | | | | | | | | | | | | |
| [removed: /S/ STEVE] [added: /s/ STEVEN R.] ALTMAN | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| [removed: /S/] [added: /s/] NICHOLAS AUGUSTINOS | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| [removed: /S/] [added: /s/] RICHARD [added: A.] COLLINS | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| Richard [added: A.] Collins | | | | | | | | | | | | | | |
| [removed: /S/] [added: /s/] KAREN DAHUT | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| [removed: /S/] [added: /s/] BRIDGETTE [added: P.] HELLER | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| Bridgette [added: P.] Heller | | | | | | | | | | | | | | |
| [removed: /S/] [added: /s/] BARBARA [added: E.] KAHN | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| Barbara [added: E.] Kahn | | | | | | | | | | | | | | |
| [removed: /S/] [added: /s/] KYLE MALADY | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| [removed: /S/] [added: /s/] JAY [added: S.] SKYLER | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| Jay [added: S.] Skyler, M.D. | | | | | | | | | | | | | | |
| [removed: /S/] [added: /s/] ERIC [added: J.] TOPOL | | | | | | Director | | | | | | February [removed: 11, 2021] [added: 14, 2022] | | |
| Eric [added: J.] Topol, M.D. | | | | | | | | | | | | | | |
[removed: DEXCOM, INC.][added: | DexCom, Inc. | | |]
[added: |] INDEX TO CONSOLIDATED FINANCIAL STATEMENTS [added: | | |]
| | | | [removed: Page] [added: Page] | | |
| [Report of Independent Registered Public Accounting [removed: Firm](#i889b093251984bfb881a094ef59c54bd_91)] [added: Firm](#i15862298089b493198685c5d6204a6cb_97)] | | | [removed: F-[2](#i889b093251984bfb881a094ef59c54bd_91)] [added: F-[2](#i15862298089b493198685c5d6204a6cb_97)] | | |
| [Consolidated Balance [removed: Sheets](#i889b093251984bfb881a094ef59c54bd_94)] [added: Sheets](#i15862298089b493198685c5d6204a6cb_100)] | | | [removed: F-[5](#i889b093251984bfb881a094ef59c54bd_94)] [added: F-[4](#i15862298089b493198685c5d6204a6cb_100)] | | |
| [Consolidated Statements of [removed: Operations](#i889b093251984bfb881a094ef59c54bd_100)] [added: Operations](#i15862298089b493198685c5d6204a6cb_103)] | | | [removed: F-[6](#i889b093251984bfb881a094ef59c54bd_100)] [added: F-[5](#i15862298089b493198685c5d6204a6cb_103)] | | |
| [removed: [Consolidated] [added: Consolidated] Statements of Comprehensive [removed: Income (Loss)](#i889b093251984bfb881a094ef59c54bd_103) | | | F-[7](#i889b093251984bfb881a094ef59c54bd_103)] [added: Income] | | |
| [Consolidated Statements of Stockholders’ [removed: Equity](#i889b093251984bfb881a094ef59c54bd_106)] [added: Equity](#i15862298089b493198685c5d6204a6cb_109)] | | | [removed: F-[8](#i889b093251984bfb881a094ef59c54bd_106)] [added: F-[7](#i15862298089b493198685c5d6204a6cb_109)] | | |
| [Consolidated Statements of Cash [removed: Flows](#i889b093251984bfb881a094ef59c54bd_109)] [added: Flows](#i15862298089b493198685c5d6204a6cb_112)] | | | [removed: F-[9](#i889b093251984bfb881a094ef59c54bd_109)] [added: F-[8](#i15862298089b493198685c5d6204a6cb_112)] | | |
| [Notes to Consolidated Financial [removed: Statements](#i889b093251984bfb881a094ef59c54bd_112)] [added: Statements](#i15862298089b493198685c5d6204a6cb_115)] | | | [removed: F-[11](#i889b093251984bfb881a094ef59c54bd_112)] [added: F-[10](#i15862298089b493198685c5d6204a6cb_115)] | | |
We have audited the accompanying consolidated balance sheets of DexCom, Inc. (the Company) as of December 31, [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] the related consolidated statements of operations, comprehensive [removed: income (loss),] [added: income,] stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2020,] [added: 2021,] and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, [removed: 2020] [added: 2021] and [removed: 2019,] [added: 2020,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2020,] [added: 2021,] in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2020,] [added: 2021,] based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February [removed: 11, 2021] [added: 14, 2022] expressed an unqualified opinion thereon.
Critical Audit [removed: Matters][added: Matter]
The critical audit [removed: matters] [added: matter] communicated below [removed: are matters] [added: is a matter] arising from the current period audit of the financial statements that [removed: were] [added: was] communicated or required to be communicated to the audit committee and that: (1) [removed: relate] [added: relates] to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.
The communication of [added: the] critical audit [removed: matters] [added: matter] does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit [removed: matters] [added: matter] below, providing a separate opinion on the critical audit [removed: matters] [added: matter] or on the accounts or disclosures to which [removed: they relate.][added: it relates.]
| | | | | | | Estimation of [removed: transaction price and] variable consideration for revenue recognition | | |
| *Description of the Matter* | | | | | | As discussed in Note 1 of the consolidated financial statements, the Company [removed: recognizes revenue based on a transaction price which reflects the net] [added: includes an estimate of variable] consideration [removed: to which] [added: in] the [removed: Company expects to be entitled. The] [added: calculation of the] transaction price [removed: is typically based on] [added: at] the [removed: contracted rates less an estimate] [added: time] of [removed: claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix.] [added: sale.] The Company estimates reductions for [added: pharmacy] rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data. | | |
| | | | | | | Auditing management’s determination of transaction price including variable consideration involved a high degree of subjectivity in evaluating management’s estimates. In [removed: determining transaction price, management develops estimates based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor. In] estimating [added: pharmacy] rebates, management applies contracted rates to estimates of products sold subject to rebate, known market events or trends and channel inventory data. | | |
| *How We Addressed the Matter in Our Audit* | | | | | | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s processes to determine [removed: transaction price and] [added: pharmacy] rebates, including the underlying assumptions. | | |
| | | | | | | Our audit procedures also included, among others, evaluating the significant assumptions and the accuracy and completeness of the underlying data used in management’s calculations. [removed: For transaction price, this included testing management’s estimate of the claim denials and historical reimbursement experience through a combination of underlying data validation by inspection of source documents and independent recalculation of management’s analysis. For rebates, this] [added: This] included testing contractual rates, management’s estimates of products sold subject to rebate, and inventory held by third parties at the end of the period, through a combination of underlying data validation by inspection of source documents, agreement to underlying contracts, review for consistency against historical data, and trending of inventory held at third parties versus inventory sold into the channel. In addition, we inspected the results of the Company’s retrospective review analysis of [added: pharmacy] rebates claimed, evaluated the estimates made based on historical experience and performed sensitivity analyses over the Company's significant assumptions. | | |
| [added: Deferred tax assets] | | | [added: 220.8] | | | [removed: Valuation allowances on deferred tax assets] | | | [added: 216.4 | | |]
| Dated: February 14, 2022 | | | | | | | | | | | | By: | | | | | | /s/ JEREME M. SYLVAIN | | |
| | | | | | | | | | | | | | | | | | | Jereme M. Sylvain, Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin R.
Sayer and Jereme M.
| /s/ JEREME M. SYLVAIN | | | | | | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | | | | | February 14, 2022 | | |
| Jereme M. Sylvain | | | | | | | | | | | | | | |
| Steven R. Altman | | | | | | | | | | | | | | |
February 14, 2022
| Intangibles and other assets, net | | | 42.0 | | | | | | 21.4 | | |
| Translation adjustments and other | | | | | | (1.0) | | | | | | 1.1 | | | | | | 0.4 | | |
| Tax benefit related to Senior Convertible Notes | | | | | | — | | | | | | — | | | | | | (1.1) | | | | | | — | | | | | | — | | | | | | — | | | | | | (1.1) | | |
| Conversions of 2023 Notes | | | | | | 0.4 | | | | | | — | | | | | | 28.7 | | | | | | — | | | | | | — | | | | | | 24.6 | | | | | | 53.3 | | |
| Benefit of note hedge upon conversions of 2023 Notes | | | | | | (0.2) | | | | | | — | | | | | | 130.8 | | | | | | — | | | | | | — | | | | | | (130.8) | | | | | | — | | |
| Net income | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 154.7 | | | | | | — | | | | | | 154.7 | | |
| Balance at December 31, 2021 | | | | | | 97.0 | | | | | | 0.1 | | | | | | 2,504.5 | | | | | | 0.5 | | | | | | (47.4) | | | | | | (206.2) | | | | | | 2,251.5 | | |
| Collaborative research and development fee | | | 87.1 | | | | | | — | | | | | | — | | |
| Shares received under note hedge upon conversion of 2023 Notes | | | $ | (130.8) | | | | | $ | — | | | | | $ | — | |
| December 31, 2021 | | | | | | | | | | | | | | |
We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash.
We estimate the fair value of most of our cash equivalents using Level 1 inputs.
We estimate the fair value of our marketable equity securities using Level 1 inputs and we estimate the fair value of our marketable debt securities using Level 2 inputs.
which approximates the related fair values due to the short-term maturities of these instruments.
We capitalize inventory produced in preparation for commercial launches when it becomes probable that the product will receive regulatory approval and that the related costs will be recoverable through the commercialization of the product.
A number of factors are considered, including the status of the regulatory application approval process, management’s judgment of probable future commercial use, and net realizable value.
Historically, our inventory reserves have been adequate to cover our actual losses.
However, if actual product life cycles, product quality or market conditions differ from our assumptions, additional inventory adjustments that would increase cost of goods sold could be required.
We also capitalize certain costs incurred for the development of enterprise-level business and finance software that we use internally in our operations.
Costs incurred in the application development phase are capitalized while costs related to planning and other preliminary project activities and to post-implementation activities are expensed as incurred.
projections and/or use of a market approach by looking at market values of comparable companies.
For transactions other than a business combination, we also capitalize as intangible assets the cost of certain milestones payable by us to collaborative partners and incurred at or after the product has obtained regulatory approval for marketing.
The intangible assets associated with these milestones are amortized over the remaining estimated useful life of the underlying asset.
In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under tax law and results of recent operations.
If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business.
We review the status of each significant matter quarterly and assess our potential financial exposure.
We base our judgments on the best information available at the time.
As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates.
Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.
*Estimates*
We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date.
| Dated: February 11, 2021 | | | | | | | | | | | | By: | | | | | | /S/ QUENTIN S. BLACKFORD | | |
| | | | | | | | | | | | | | | | | | | Quentin S. Blackford, Chief Operating Officer and Chief Financial Officer (Principal Financial Officer) | | |
| /S/ QUENTIN S. BLACKFORD | | | | | | Chief Operating Officer and Chief Financial Officer (Principal Financial Officer) | | | | | | February 11, 2021 | | |
| Quentin S. Blackford | | | | | | | | | | | | | | |
| Steve Altman | | | | | | | | | | | | | | |
| *Description of the Matter* | | | | | | As discussed in Note 8, significant judgment is required to evaluate the need for a valuation allowance against deferred tax assets. The Company reviews all available positive and negative evidence, including projections of pre-tax book income, earnings history, reliability of forecasting, and reversal of temporary differences. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized. Realization of deferred tax assets is dependent upon future earnings. Prior to 2020, due to the Company’s U.S. operating losses and earnings volatility in previous years, which did not allow sustainable profitability, the Company had established and maintained a full valuation allowance on its deferred tax assets. In 2020, the Company achieved three years of cumulative income. The Company analyzed both positive and negative evidence, and as a result, released its valuation allowance of $287.2 million on its deferred tax assets. The Company maintains a valuation allowance of $55.5 million against its California research and development tax credits and certain foreign intangible assets, as it is more likely than not that those deferred tax assets will not be realized. | | |
| | | | | | | Auditing management's analysis of the realizability of the deferred tax assets was complex and highly judgmental because the assessment process involves significant judgment and subjective evaluation of assumptions that may be affected by future operations of the Company, market or economic conditions. | | |
| *How We Addressed the Matter in Our Audit* | | | | | | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s process to assess the realizability of the deferred tax assets and measurement of the valuation allowances, including controls over management’s scheduling of the future reversal of existing taxable temporary differences, identification and use of available tax planning strategies and projections of future taxable income. | | |
| | | | | | | Among other audit procedures performed, we tested the reversal of the existing taxable temporary differences, including assessment of the completeness and accuracy of related schedules. We evaluated the assumptions used by the Company to develop projections of future taxable income by jurisdiction. For example, we compared the projections of future taxable income with the actual results from prior periods, as well as management’s consideration of current trends. We also considered the relevant tax laws and regulations in the various jurisdictions, including considering whether the estimated future sources of taxable income were of the appropriate character to utilize the deferred tax assets. We also considered the accuracy of management’s historical projections and performed sensitivity analyses of the significant assumptions to evaluate the changes in realizability of deferred tax assets that would result from changes in the assumptions. In addition, we evaluated the Company’s income tax disclosures related to the matters described above. | | |
February 11, 2021
| Foreign currency translation gain | | | | | | 1.1 | | | | | | 0.4 | | | | | | 4.0 | | |
| Balance at December 31, 2017 | | | | | | 87.0 | | | | | | $ | 0.1 | | | | | $ | 1,093.7 | | | | | $ | (2.6) | | | | | $ | (671.8) | | | | | $ | — | | | | | $ | 419.4 | |
| Convertible note hedge | | | | | | — | | | | | | — | | | | | | (218.9) | | | | | | — | | | | | | — | | | | | | — | | | | | | (218.9) | | |
| Equity component of convertible 2023 Note issuance, net of issuance costs | | | | | | — | | | | | | — | | | | | | 171.6 | | | | | | — | | | | | | — | | | | | | — | | | | | | 171.6 | | |
| Sale of warrants | | | | | | — | | | | | | — | | | | | | 183.8 | | | | | | — | | | | | | — | | | | | | — | | | | | | 183.8 | | |
| Net loss | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (127.1) | | | | | | — | | | | | | (127.1) | | |
| Non-cash collaborative research and development fee through issuance of common stock | | | — | | | | | | — | | | | | | 217.7 | | |
| Unrealized gain on equity investment | | | — | | | | | | — | | | | | | (36.0) | | |
| Purchases of treasury stock | | | — | | | | | | — | | | | | | (100.0) | | |
| Proceeds from sale of warrants | | | — | | | | | | — | | | | | | 183.8 | | |
| Purchase of convertible note hedge | | | — | | | | | | — | | | | | | (218.9) | | |
The functional currencies of our international subsidiaries are generally the local currencies.
In this step we allocate the fair value of the
Significant judgment is required to evaluate the need for a valuation allowance against deferred tax assets.
We review all available positive and negative evidence, including projections of pre-tax book income, earnings history, reliability of forecasting, and reversal of temporary differences.
Realization of deferred tax assets is dependent upon future earnings in applicable tax jurisdictions.
Prior to 2020, due to our US operating losses and earnings volatility in previous years, which did not allow sustainable profitability, we had established and maintained a full valuation allowance on our deferred tax assets.
In 2020, we achieved three years cumulative income and expect to continue that profitability in future years.
We analyzed both positive and negative evidence, and as a result released our valuation allowance on our deferred tax assets.
Significant judgment is required in the determination of whether a potential loss is probable, reasonably possible, or remote as well as in the determination of whether a potential exposure is reasonably estimable.
*Policy Elections and Practical Expedients Taken*
- We report revenue net of taxes collected from customers, which are subsequently remitted to governmental authorities;
- We account for shipping and handling activities that are performed after a customer has obtained control of a good as fulfillment costs rather than as separate performance obligations;
- We do not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; and
- If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a significant financing component.
We classify our provisions related to variable consideration
Unbilled accounts receivable consists of revenue recognized for Components we have delivered but not yet invoiced to customers.
In June 2016, the FASB issued ASU 2016-13, *Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments*, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities.
In addition, the outbreak of the novel strain of coronavirus, SARS-CoV-2 (“COVID-19”), has not had a significant impact on our expected credit losses or our consolidated financial statements during 2020.
We are continuing to monitor the impact of COVID-19 on expected credit losses.
An excerpt. Shown here: 40 of 526 rewritten, 40 of 164 added and 40 of 183 removed. The counts are complete. For every sentence, read Item 16. FORM 10-K SUMMARY in the FY2021 filing and the FY2020 filing.